Doctor of Philosophy by De bever, Joshua Thomas
ADAPTIVE MODEL-PREDICTIVE CONTROL AND 
3D ACOUSTIC RADIATION FORCE IMAGING 




Joshua Thomas de Bever
A dissertation submitted to the faculty of 
The University of Utah 
in partial fulfillment of the requirements for the degree of
Doctor of Philosophy 
in
Computing
School of Computing 
The University of Utah 
May 2015
Copyright © Joshua Thomas de Bever 2015 
All Rights Reserved
T H E  U N I V E R S I T Y  O F  U T A H  G R A D U A T E  S C H O O L
STATEMENT OF DISSERTATION APPROVAL
The dissertation of
Joshua Thomas de Bever





















and by Ross Whitaker, Chair of the School of Computing, and by David B. Kieda, 
Dean of The Graduate School.
ABSTRACT
Focused ultrasound (FUS) is a promis ing noninvasive and radiation-free cancer 
therapy that selectively delivers high-intensity acoustic energy to a small target 
volume. This dissertation presents original research that improves the speed, safety, 
and efficacy of FUS therapies under magnetic resonance imaging (MRI) guidance.
First, a new adaptive model-predictive controller is presented that leverages the 
ability of MRI to measure temperature inside the patient at near real-time speeds. The 
controller uses MR temperature feedback to dynamically derive and update a patient- 
specific thermal model, and optimizes the treatment based on the model’s predictions. 
Treatment safety is a key element of the controller’s design, and it can actively protect 
healthy tissue from unwanted damage. In vivo and simulation studies indicate the 
controller can safeguard healthy tissue and accelerate treatments by as much as 50%. 
Significant tradeoffs exist between treatment speed, and safety, which makes a real­
time controller absolutely necessary for carrying out efficient, effective, and safe 
treatments while also highlighting the importance of continued research into optimal 
treatment planning.
Next, two new methods for performing 3D MR acoustic radiation force imaging 
(MR-ARFI) are presented. Both techniques measure the tissue displacement induced 
by short bursts of focused ultrasound, and provide a safe way to visualize the 
ultrasound beam’s location. In some scenarios, ARFI is a necessity for proper targeting
since traditional MR thermometry cannot measure temperature in fat. The first 
technique for performing 3D ARFI introduces a novel unbalanced bipolar motion 
encoding gradient. The results demonstrate that this technique is safe, and that 3D 
displacement maps can be attained time-efficiently even in organs that contain fat, 
such as breast. The second technique measures 3D ARFI simultaneously with 
temperature monitoring. This method uses a multi-contrast gradient recalled echo 
sequence which makes multiple readings of the data without increasing scan time. This 
improves the signal to noise ratio and makes it possible to separate the effects of tissue 
heating vs displacement.
Both of the 3D MR-ARFI techniques complement the presented controller since 
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This dissertation presents work done to improve the speed, safety, and efficacy 
of magnetic resonance-guided focused ultrasound (MRgFUS) thermal therapies. 
While MRgFUS offers many potential benefits, the primary thrust of this work is to 
advance MRgFUS as a noninvasive and radiation-free cancer therapy.
Focused ultrasound bears similarity to diagnostic ultrasound imaging, but 
differs by delivering high intensity acoustic energy to a small volume and in a highly 
selective manner. Furthermore, the goal of FUS is to generate mechanical or thermal 
tissue effects instead of images. Applications of focused ultrasound are growing rapidly 
and currently include: mechanical fractionation of tissue (histotripsy), adjuvant 
hyperthermia, blood-brain barrier opening, assisted drug delivery, neuromodulation, 
and pain palliation.
This work focuses on thermal ablation of cancer where a variety of organs are 
currently being targeted including brain, breast, uterus, and liver, among others. 
Magnetic resonance (MR) imaging adds powerful new capabilities to ablative FUS 
procedures. First, MRI provides excellent soft tissue contrast for anatomical imaging, 
tumor identification, treatment planning, and post-treatment assessment. Second, MR 
thermometry makes it possible to continuously monitor the temperature inside the
patient during treatment. Third, acoustic radiation force imaging, offers the ability to 
interrogate the mechanical properties of tissue.
Despite these advantages, significant technical challenges impede the 
widespread adoption of MRgFUS in clinics. First, MRgFUS treatments take an 
extended period of time, both in treatment planning and patient setup stages, and in 
the treatment itself. This adds to the cost of MRgFUS therapy and leads to patient 
discomfort. Second, while MR thermometry provides vital temperature feedback, the 
interval between measurements is still long compared to the rate of tissue damage at 
higher temperatures. This leads to excessive treatment of the tumor, which wastes time 
and compromises the safety of normal tissues not at the focus, but in the beam path. 
Third, accurate positioning of the focal positions is critical to providing safe and 
effective treatments, but standard beam localization methods using low-power 
interrogation pulses risk causing unwanted tissue damage.
This dissertation presents progress toward addressing these challenges and is 
divided into five sections. In the remainder of Chapter 1, background theory on MRI 
and focused ultrasound is presented. Chapter 2 presents original results into improved 
control of MRgFUS using a new adaptive model-predictive controller (AMPC). The 
AMPC aids in accelerating MRgFUS treatments while also mitigating safety concerns 
through direct safeguards of healthy tissue. Chapters 3 and 4 present two methods for 
improved focal spot localization using 3D acoustic radiation force imaging. These 
techniques enable time-efficient visualization of the tissue displacement induced by a 
short burst of ultrasound, and are shown to be a safe alternative to standard 
approaches. Additionally, 3D ARFI is shown to work in tissue environments
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containing fat where standard MR thermometry is ineffective. Both ARFI techniques 
presented encode tissue displacement into the phase of the image, however, the work 
in Chapter 3 presents a new motion encoding scheme used in a spin-echo sequence 
while Chapter 4 presents a multicontrast gradient recalled echo sequence which can 
simultaneous measure tissue displacement and temperature. These two 3D ARFI 
approaches are directly applicable to the AMPC as it requires accurate focal spot 
positioning to provide fast, effective, and safe MRgFUS treatments. Lastly, Chapter 5 
summarizes the tasks accomplished and describes avenues for future investigation.
1.2 Principles of Magnetic Resonance Imaging
1.2.1 Benefits of MRI 
Magnetic resonance imaging offers several advantages including the ability to 
noninvasively acquire high-resolution images with excellent soft-tissue contrast 
without ionizing radiation. The MR signal is dependent on many physical and system 
parameters, which has led to the development of numerous types of signal contrast 
that visualize differences among tissues in unique ways. MRI’s flexibility has found 
wide ranging application including the identification of normal and cancerous tissue, 
functional mapping of the brain’s internal networks, and monitoring of tissue changes 
over time. The lack of ionizing radiation makes it safer than modalities like X-ray 
computed tomography, and can produce more detailed images than ultrasound. A 
unique aspect of MRI is that the signal measured is derived from the sample itself, as 
opposed to X-ray techniques where the internal structures are inferred from the 
transmission (or lack thereof) of an external X-ray beam, or positron emission 
tomography (PET) where radioactive material is put into the body and the positrons
3
4that escape account for the detected signal.
1.2.2 M RI Hardware Components 
A typical MRI scanner consists of three principal hardware systems: (1) a 
primary superconducting magnet, (2) a set of resistive gradient coils, and (3) a radio 
frequency (RF) coil. The closely coordinated operation of these systems generates, 
encodes, and detects a signal, which is then reconstructed to produce images.
The primary superconducting magnet (Figure 1.1) is responsible for producing 
a strong and uniform magnetic field, B0, which polarizes the sample within the bore of 
the MRI. Field strengths produced by clinical MRI systems currently range from 
approximately 1 -  3 Tesla, and the field produced by these systems are typically 
homogeneous to 3 ppm over a spherical volume 40-70 cm in diameter. So called “high- 
field” full body MRI scanners currently in development can achieve 7-11 T. Stronger 
main field strengths are desirable because they increase the degree of sample 
polarization and thus increase the amount of signal available for measurement. 
However, the homogeneity of the B0 field is also critical to successful MRI imaging. 
Homogeneity of the main field is usually enhanced with both passive and active field
Figure 1.1: Schematic of the principal systems of an MRI.
“shimming” devices. Iron or steel blocks are inserted into the bore during installation 
of the main magnet to improve static field homogeneity, while special shim coils carry 
small currents, which can be adjusted for each subject, to generate magnetic fields that 
cancel out unwanted field deviations.
Radio frequency (RF) coils are responsible for both exciting the sample and 
detecting the resulting signal. Excitation is performed by generating a secondary time- 
varying magnetic field, B1, which is perpendicular to B0. After excitation, the RF coil 
is switched into “Receive Mode,” and the voltage induced in the RF coil by the sample 
is recorded. The induced voltage recorded is the fundamental MR signal that forms all 
images. RF coils derive their name from the fact that the frequency of the time-varying 
currents they carry (typically 40 -  130 MHz for clinical systems) overlaps with the FM 
radio frequency spectrum. A single RF coil can be used to both excite the sample and 
measure the induced signal, and such coils are called transmit/receive coils. However, 
to maximize the signal to noise ratio (SNR), it is advantageous to place the receive coil 
as close as possible to the sample. Consequently, it is common to use the RF coil 
integrated into the bore of the magnet (sometimes called the body coil) to excite the 
sample while receiving with a separate coil closer to the volume of interest.
Gradient coils are resistive electromagnets that make imaging possible by 
spatially encoding the signal. A set of three gradient coils, one for each Cartesian axis, 
generate small magnetic fields that modulate Bz linearly along the x, y, and z  directions. 
The magnetic field gradients produced are in the range of 10 -  50 m T/m  for human 
MRI systems, but can be upward of 1000 m T/m  for dedicated small animal systems.
The following sections describe in more detail how MRI generates and detects
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6a signal, and how that signal is used to form images. The following references are also 
excellent resources for additional information and derivations [1]-[4].
1.2.3 Producing a Net Magnetization 
In 1922, German physicists Otto Stern and Walther Gerlach, performed an 
experiment that demonstrated that the angular momentum of silver came only in 
quantized values. Work in quantum mechanics later explained this result was due to 
an intrinsic quantum mechanical property of particles called spin angular momentum, 
or “spin.” Bosons can possess only integer spin (0, 1, 2, ...), while Fermions (such as 
electrons, protons, and neutrons) can possess only nonzero multiples of V2 integer spin 
(2, | ,  §,...). Consequently, the net spin of atomic nuclei (which are composed of 
Fermions) can take on only multiples of 0, V-integer, or full-integer spin. When a 
particle with spin ^ 0 is placed in a static magnetic field, its spin angular momentum 
will precess, or rotate, about the applied field at a frequency called the Larmor 
Frequency given by:
^ o = l Bo (1.1)
where 7 is the gyromagnetic ratio (a nuclei specific proportionality is constant). This 
linear relationship between frequency of precession and field strength will prove 
important later when image formation is discussed.
Though imaging of other nuclei, such as 3H, 13C, 19F, 31P, and 23Na (which has 
spin 3/2) is possible, the most commonly imaged nucleus is *H (spin V) primarily 
because of its high natural abundance in the human body and large gyromagnetic ratio
(see Table 1.1).
Since MR imaging in this work was entirely based on *H, the remainder of this 
discussion will assume a spin V2 system. When such a system is placed in a static 
magnetic field, its spins can inhabit a superposition of only two energy states: aligned 
parallel to Bo (low-energy state) and aligned antiparallel to Bo (high-energy state). This 
is called Zeeman Splitting (or the Zeeman Effect), and the ratio of the probability of 




^  =  e x p l  ~ W (1.2)
where k = 1.38x10"23 J/°K  is the Boltzman constant, T  is absolute temperature in °K, 
and A E  is the energy difference between parallel and antiparallel states. To a first order 
approximation, A E  = 7hB0 where h = h/2n  and h is Planck’s constant 6.6 x 10"34 
J • s. At a field strength of 3 T and body temperature of 310 °K, the population 
difference between N T and is approximately 10 parts per million. This small
Table 1.1 : Properties of selected nuclei






Frequency at 3T 
[MHz]
*H 1/2 88 M 42.576 127.7
13C 1/2 0 M 10.705 32.1
i9F 1/2 4 |iM 40.052 120.2
23Na 3/2 80 mM 11.262 33.8
31p 1/2 75 mM 17.235 51.7
difference is one reason higher field strengths are desirable; however, an observable 
signal is still generated due to the large number of spins contained in the system.
A charged particle with spin %, such as a proton, behaves like a small electrical 
current, and thus produces a magnetic field much like a bar-magnet. It is useful to 
consider an entire population of spins so that quantum mechanical effects can be 
simplified to a classical picture. Without the influence of a magnetic field, the thermal 
energy possessed by each spin of the group serves to randomize their orientations. 
Thus there will be no net magnetization since each spin’s magnetic moment will be 
canceled by another in the population. Once placed in a static field however, a net 
positive number of spins will align with the field (Zeeman Splitting), and the 
summation of the spin’s moments will produce a net magnetic moment, M0, along the 
direction of Bo. This is the classical picture of net magnetization that will be used in 
the following sections. After reaching equilibrium, the net magnetization vector points 
along the z-direction and has magnitude given by:
|M o |= M 0 = ^ ^ § ^  (I.3)
where Ns is the number of spins in the sample.
1.2.4 Nuclear Magnetic Resonance and Signal Generation 
At this stage, the spins subjected to B0 are precessing, and there is a net 
magnetization (Mo) along z due to the alignment of the spins, but it is important to 
note that Mo is not precessing about Bo and thus there is no observable signal. To 
generate a signal, Mo must be perturbed from equilibrium. This is done using nuclear
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magnetic resonance (NMR), a discovery made by Isidor Isaac Rabi in 1938 for which 
he was awarded the 1944 Nobel Prize in physics. Rabi discovered that a system with 
spin ^  0 would absorb, and then release, energy if excited by a magnetic field oscillating 
at a resonant frequency in a direction perpendicular to B0. The resonant frequency 
turned out to be the Larmor F requency (Eqn (1.1)), which was discovered in a different 
context decades earlier by Sir Joeseph Larmor in 1897. The Dutch physicist Cornelius 
J. Gorter proposed NMR theoretically one year before Rabi, however, Rabi was first 
to demonstrate the effect experimentally. To tip M0, composed of *H nuclei residing in 
a 3 T field, away from B0, the transmitted B1 field must oscillate at the Larmor 
Frequency of 127.7 MHz (Table 1. 1). This excitation pulse is commonly referred to as 
an RF pulse. Once M0 has a component in the xy (or transverse) plane, it begins to 
precess about B0. The angle that M0 is tipped from B0 is called the flip angle (FA), and 
this can be adjusted by varying the duration and/or the amplitude of the transmitted 
B1 field. The achieved flip angle can be calculated from the Bloch equations, and 
reduces to:
rTrf
a FA= I j B 1(t)dt (1.4)
0
where a FA is the resulting flip angle, B 1 (t) is the applied, time-varying, RF pulse, and 
Trf is the duration that Bj is applied (usually on the order of milliseconds). Note that 
the excitation is nucleus specific and that this allows the selective excitation of one 
nucleus without disturbing any others. Common flip angles needed for MR imaging
9
are 90° (shown in Figure 1.2), which results in all of M0 being transferred into the 
transverse plane, and 180°, which mirrors the entire spin system about the x  or y  axis.
1.2.5 Signal Detection 
If a receiving RF coil is placed near the precessing magnetization, a voltage will 
be induced in the coil due to Faraday’s Law. This voltage is the fundamental signal in 
MRI. It is necessary to tune the receiving RF coil circuit such that it resonates at the 
Larmor Frequency, and consequently different RF coils must be designed for every 
nuclei and for each field strength.
1.2.6 Longitudinal and Transverse Relaxation 
The magnetization tipped into the transverse plane represents the signal 
available for detection; however, the system is now out of equilibrium. After the RF
10
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pulse, Mz restores to Mo exponentially with a characteristic time constant, T1. This 
process is called longitudinal relaxation, and the value of T1 varies for each tissue type. 
The restoring of M z can be modeled by the Bloch equations, and the solution, 
assuming M z(0) is the remaining magnetization along the z-axis immediately after the 
RF pulse, is given by:
Relaxation of the magnetization also occurs in the transverse plane, 
independently of longitudinal relaxation, and is described by an exponential decay 
with time constant T2:
where M xy (0) is the magnetization initially tipped into the transverse plane by the RF 
pulse. This relaxation process also varies by tissue type, and imposes limits on the 
duration available for sampling the MRI signal. Table 1.2 summarizes values of T1 
and T2 for several tissues. For liquids, T2 is relatively long, while for solids it tends to 
be shorter. It is always the case that T1 is longer than T2.
Unfortunately, Eqn (1.6) for T2 is for a highly idealized case and many factors, 
such as field inhomogeneity or interactions among spins, will cause the signal to decay 
faster than T2 predicts. A second transverse relaxation rate, T2*, is frequently used as 
an effective decay rate that accounts for static field inhomogeneities. It relates to T2 
by the relation:
M z(t) = M°Z( 1 -  e-t/T1) +  M z(0)e-t/T1 (1.5)
(1.6)
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i i  =  f5  +  7AB» (1'7)
Even this deviates from reality, however, it is a commonly used and useful 
approximating function.
1.2.7 Free Induction Decay 
All 2D and 3D MR imaging is underpinned by a much simpler experiment 
called a free induction decay (FID). As a first example, assume a sample with a single 
group of spins (T1 = 500 ms, T2 = 50ms), which do not interact with one another, and 
who experience a uniform magnetic field. Starting from equilibrium such that Mz = 
M0, and Mxy = 0, a 90° RF pulse is applied and subsequently Mxy = M0, while Mz 
= 0. The net magnetization begins to precess around B0, and the rotating transverse 
magnetization induces a voltage in the receiving RF coil. This signal is given by:
S(t) = M0 sin(aFA)e-t/T2e-lWot (1.8)
As the rotating My  changes its orientation with respect to the receiver RF loop, so does
the magnetic flux and induced voltage, and so the signal recorded oscillates between 
+ /- its maximum value at the Larmor Frequency (Figure 1.3a). As time passes, the 
signal amplitude is bounded by an exponential decay envelope, and after one T2 
interval, 63% of the initial transverse magnetization has been lost. By five T2 intervals, 
nearly all the signal has been lost. Conversely, Mz recovers approximately 63% of its 
equilibrium value after one T1 interval.
Now consider a second example where there are two spin groups with the same 
T1 and T2 as before, but who experience different magnetic fields due to an 
inhomogeneity of Bo. The result is that each group precesses at a slightly different 
frequency which causes the transverse magnetization to decay at a rate of T2* instead 





















Figure 1.3: Signal from a single spin group compared to that of two spin groups. (a) 
FID from a single spin group in a uniform field. Dashed line indicates signal decay 
envelope at a rate of T2. (b) FID from a sample with two spin groups experiencing 
different fields due to inhomogeneity of Bo. FID decays at T2*, faster than T2 (dashed 
lined). Note: Larmor Frequency reduced to make oscillations more visible.
1.2.8 Image Formation in 2D and 3D
In the FID experiment, nothing can be done about the field inhomogeneities 
that increased the rate of signal loss, and so the optimal time to measure the signal is 
immediately after the RF pulse. This is problematic for MR imaging because the 
additional steps required before the signal can be measured (to be discussed later) result 
in significant signal decay. There are two commonly used techniques that recover 
some of the lost signal by creating a signal echo after a user defined delay called the 
echo time (TE). These techniques have the additional advantage of affording some 
flexibility in selecting when to measure the signal.
1.2.8.1 Gradient recalled echoes
The first approach to creating a signal echo is to apply an intentional field 
gradient along one direction, say the x direction, which adds phase to the spins and 
reduces the signal. Then, the gradient polarity is reversed causing the phase of the spins 
to decrease and eventually refocus to produce a signal echo. This is called a gradient 
recalled echo (GRE) and is illustrated in Figure 1.4. This technique tends to be fast, 
but cannot compensate for static field inhomogeneities and thus the signal decays as 
T2* instead of T2.
1.2.8.2 Spin-echoes
Figure 1.5 demonstrates the spin-echo (SE) approach to forming a signal echo. 
By adding an additional RF pulse with a 180° flip angle at a time TE/2 after the initial 
excitation RF pulse, the spin system will be mirrored such that the spins’ accrued phase 
in the transverse plane is negated. As the spins continue to precess after the 18o° pulse,
14
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Figure 1.4: Gradient recalled echo generated at TE by applying gradients to 
intentionally dephase the spins, then rewinding the spins with an opposing gradient 
which forms an echo at TE. Signal decays with T2*, faster than T2, and static field 
inhomogeneities are not reversed.
0 20 40 60 80 100 
Time [ms]
Figure 1.5: Spin-echo generated at TE by applying a 180° pulse at TE/2. Signal decays 
with T2, but static field inhomogeneities are reversed to recover more signal at t = TE.
they will come back into phase at t = TE creating a signal echo. One major advantage 
of the SE approach over the GRE approach is that the effect of static field 
inhomogeneities will be canceled out at the echo time because the spins encounter the 
same field deviations after the 180° pulse as they did before the 180° pulse. As a result, 
the signal decays at a rate of T2 (which is not reversible) instead of T2* as in the GRE 
case. The downside of the SE method is that it requires an additional RF, which takes 
time and deposits additional energy into the sample. The 180° pulse can also induce 
new, unwanted, signal that can corrupt the image.
1.2.8.3 Frequency and phase encoding
Up to this point, NMR has been used to induce a FID signal which is a measure 
of the bulk magnetization in the sample. However, to assemble a 2D image, a method 
for localizing where the signal came from must be developed. It may seem obvious 
now that the equation for the Larmor Frequency, u  = 7B 0 , gives us a method for 
accomplishing this, but the technique, first published in 1973, won Paul Laterbur a 
Nobel Prize. By modulating the large B0 field by imposing an additional field that 
varies linearly across one dimension, for example the x direction, the precession 
frequency becomes a function of position given by:
u(x) = 7 (B0 + Gxx) (1.9)
where Gx(x) describes the gradient field in T/m. This is called frequency encoding. 
For a real object, the signal measured is now a function of the density of spins, p(x), 
and the position of those spins along the x  direction:
16
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S(x, t )  = f  p(x)e ljGxXtdx (1.10)
where the baseline frequency u 0 has been subtracted. It is important to note that the 
fact that the gradient is linear and of known magnitude is critical for accurate spin 
localization. A skilled pianist sitting at their piano blind folded can determine the 
location of keys that produce low pitch notes (to their left) vs high pitched notes (to 
their right) because they are familiar with the ordering of the piano. Similarly, the 
known gradient makes it possible to map the measured frequency to a location along 
the x axis. It is common to refer to the axis being frequency encoded as the “readout 
direction.” There remains one problem; every yz  plane at a given x position has been 
assigned the same frequency and cannot be separated.
To solve this, an additional form of spatial encoding, called phase encoding 
(PE), is performed. Similar to frequency encoding, a linearly varying magnetic field, 
produced by the gradient coils, is applied along a direction perpendicular to the 
readout direction, commonly referred to as the phase encode direction. The phase 
encoding gradient is only enabled for a brief amount of time, but while enabled, it 
causes spins along the PE-direction to accrue a phase proportional to the time the PE 
gradient is enabled and their position along the PE direction. Thus, if the PE direction 
is along the y  axis, and the field is given by Gy(y) in T/m , then the phase of the spins 
along y  is now:
/r PEj G y(t)y dt (1.11)
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This can be thought of as a gradient-time area, or gradient moment, and explains that 
for a given phase/area, time can be exchanged for higher amplitude or vice versa. An 
ideal gradient system turns on and off instantaneously, and under this idealization, 
Eqn (1.11) reduces to:
The last dimension (the z axis but generally referred to as the slice direction) is 
localized by selectively exciting a plane (2D imaging), or volume (3D imaging). The 
NMR concept says that an RF pulse only excites spins that share its resonant 
frequency. By applying a third gradient along the slice direction, spins will resonate at 
a range of frequencies, and by designing the RF pulse carefully so as to match the 
bandwidth of the desired spins, only a small slice of the object will be excited. 
Consequently, parts of the sample not in the slice will not generate a signal because 
their magnetization remains aligned with B0 and not in the transverse plane. For 2D 
imaging, it is sufficient to perform this slice selective RF pulse and perform phase and 
frequency encoding. Multiple 2D slices can be acquired to increase the coverage of the 
sample. Alternatively, a 3D acquisition can be accomplished where the selective 
excitation is performed over a thick slice (a slab) that encompasses the entire volume 
of interest, and a second set of phase encoding is required along the z direction to
0 (^) =  TPEl G y(y) (1.12)
And the updated signal equation is:
(1.13)
19
resolve spins within the excited volume.
1.2.8.4 Sampling k-space and the Fourier transform reconstruction
A unique aspect of MRI is that the data acquired represent samples of the 
spatial-frequencies of the object. This spatial-frequency domain is referred to as 
k-space. In order to generate an image that accurately represents the object, k-space 
sampling must satisfy the Nyquist sampling criteria. As shown in Figure 1.6, for a 
square field-of-view (FOV) and desired resolution (Ax) the required k-space sampling 
parameters are calculated from:
A k x = —l—  W k x = ^ ~  (1.14)
x FOV kx A x
A useful analogy is to think of k-space as an “Etch-a-Sketch” where the knobs are the 
frequency encoding gradient (which moves the sampling point along kx) and the phase 
encoding gradient (which moves along ky). The gradient amplitude controls how fast 
k-space is traversed. The complex signal on the RF receive coil is a single point of 
k-space, which is sampled by an analog-to-digital converter (ADC). Once all the 
required k-space samples are collected, the data are transformed into image space using 
a Fourier transform.
The timing diagram in Figure 1.7 shows how two lines of k-space could be 
sampled using a 2D spin-echo acquisition. First, slice-selective excitation is performed. 
Immediately after excitation, the sampling point is at the center of k-space. The first 
line of k-space to be acquired is ky = 0, so no phase encoding gradient is required. A
20
Figure 1.6: MRI samples (black dots) of the object’s spatial-fTequencies in k-space. 
After sufficient sampling of k-space, a Fourier transform is performed to generate an 
image. Width of the square field-of-view is FOV and the voxel size is A^. From these 
quantities, it is possible to solve for the required k-space sampling interval and 






Figure 1.7: Example of Cartesian sampling of two k-space lines using a 2D spin-echo 
acquisition. Black dots indicate sample locations measured during the current 
excitation. Gray dots are samples acquired during other excitations. Dashed gray lines 
indicate the linear traversal between two circled locations in k-space without acquiring 
data. Solid gray lines indicate that data are being acquired at an interval At  while 
moving linearly between two circled locations. Numbers indicate the ordering of 
events as they unfold due to the timing diagram.
fast way to sample data along the frequency encode (readout) direction is to start at 
the -kx edge and traverse at constant speed toward +kx while sampling at an 
appropriate time interval, At. To accomplish this, a negative readout gradient moves 
to - k max, and then a positive, constant, gradient is applied to move toward +krnax. 
For a given readout gradient amplitude and A k x, the sampling interval A t  is given by:
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t = lG~x x = iG xFOV (L15)
This completes the acquisition of one line of k-space. The entire process is then 
repeated for ky = 1 where, after the excitation, the sampling point is again at kx = 
ky = 0. To move to ky = 1, the phase encode gradient must be applied. As higher ky 
frequencies are sampled, the phase encoding gradient area required grows. Normally, 
the duration of the phase encoding gradient is kept constant, so to cover a larger ky 
distance in the same time, it is necessary to increase the gradient amplitude. Assuming 
a phase encode duration of tpe , the PE gradient amplitude increment can be calculated 
by:
A G 'J lTPEA k » 1tpeFOV (U 6 )
The acquisition of each kx line requires a new excitation pulse. The time 
between repeated excitation pulses, TR, is an important parameter that determines the 
total amount of time it will take to acquire all lines of k-space, and how much
longitudinal relaxation will occur between of each acquisition along kx. Another 
fundamental sequence parameter is the echo time TE. Note that the echo was formed 
as kx = 0 was acquired. The center frequencies tend to be most important to the image, 
so it is advantageous to sample them when the signal is maximal. The process is similar 
for 3D acquisitions except for the additional kz phase encoding steps which require 
more repetitions.
1.2.9 MR Thermometry 
The first method for measuring temperature with MRI was published in 1983 
and was based on the temperature dependence of the longitudinal relaxation time 
constant, T1 [5], [6]. It was found that T1 varied linearly over small temperature ranges 
and could thus be used to measure absolute temperature. This technique did not gain 
widespread popularity in part because T1 mapping is time consuming, and also 
because T1 varies across multiple parameters including tissue type and field strength.
The most popular MR thermometry method, which is used exclusively in this 
work, is the proton resonance frequency shift technique [7], [8]. As the name implies, 
when protons in water heat up, their resonant frequency changes by 
approximately -0.009 ppm/°C. The reduction in resonant frequency is a result of 
increased shielding of the hydrogen atom by the electrons on the oxygen atoms in 
water. The increased shielding reduces the effective local magnetic field experienced 
by the hydrogen atom, resulting in a frequency reduction. When tissue warms, the 
hydrogen protons precess about B0 at a slower rate, and thus a phase difference will 
accrue over time.
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The PRF method is normally used in conjunction with a GRE pulse sequence 
since the refocusing 180° RF pulse in SE sequences would cancel out most of the phase 
accrued due to temperature. The phase difference for a series of measurements over 
time is computed by subtracting a baseline phase image from each time frame. The 
change in phase can then be converted to a change in temperature, AT, via:
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A T  = A $i (1 17)
PlBoTE  ( )
where A ^ t is the total phase change relative to the baseline for the i-th measurement, 
and P is the previously mentioned proportionality constant -0.009 ppm/°C. There is a 
tradeoff in selecting the value of TE since a longer TE results in more T2* signal loss 
(which reduces SNR) but provides more time for phase to accrue (which increases 
phase-SNR). Generally, a TE «  T2* strikes a good balance between these parameters.
It is fortunate that p is linear and relatively independent of tissue type over 
typical temperature ranges since it facilitates temperature monitoring in most tissue 
without advanced calibration. One notable exception to this is fat, which does not 
experience a temperature-dependent frequency change, and thus cannot be monitored 
with the PRF technique. This is especially problematic for MRgFUS applications in 
the breast.
1.3 Principles of Focused Ultrasound Thermal Therapies
1.3.1 Overview
The term “ultrasound” refers generally to any sound wave of a frequency above 
that of human hearing. Typical applications of ultrasound use frequencies above 20 
kHz up to 10 MHz, though frequencies can extend to several hundred MHz [9]. At a 
simple level, sound is a mechanical vibration of particles that propagates by contact 
with other particles. As particles come into contact and compress, a pressure above 
static pressure is generated, and this pressure field is propagated through most 
biological tissue. A common method of producing ultrasound waves is using 
piezoelectric materials that compress and expand in response to an applied voltage. 
These devices are called ultrasound transducers because they convert electrical energy 
into mechanical energy (ultrasound). However, the effect works in reverse as well; 
deformation of the piezoelectric element by an incident pressure wave will generate a 
voltage. This forms the basis for ultrasound detection and medical imaging via 
ultrasound.
Ultrasound has proved to be an invaluable tool in medical imaging because it 
is safe, portable, inexpensive, and provides high frame rates. In contrast, focused 
ultrasound is not used for imaging, but instead aims to modify tissue through either 
mechanical or thermal effects. To accomplish this, higher powers are often required. 
The effects of high-power ultrasound were noted as long ago as 1920 when Paul 
Langevin placed his hand in a water tank insonified with high-intensity ultrasound 
and discovered that pain was induced [10]. In the 1940s Lynn and Putnam first used 
focused ultrasound to produce cerebral lesions [11], [12], but in doing so also
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discovered how difficult it is to transmit ultrasound through bone. Soon after, in the 
1950s, the Fry Brothers in collaboration with Meyers would demonstrate focused 
ultrasound surgery in the brain by first performing a craniotomy [13], [14]. The 
development of new materials, new technologies such as MR thermometry, and 
increased computational power have led to a resurgence of focused ultrasound 
research. For example, it is now possible to transmit meaningful amounts of energy 
through an intact skull utilizing beam refocusing algorithms that make use of CT/MRI 
to measure the skull’s thickness. [15]. Furthermore, real-time MR thermometry makes 
it possible to monitor the progress and safety of cancer therapies performed by focused 
ultrasound.
1.3.2 Wave Propagation 
The following will assume that a transducer is positioned as shown in Figure 
1.8, and that this transducer produces a wave of frequency f  [Hz]. The mechanical
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Longitudinal
Figure 1.8: Phased array transducer. D = Diameter. lf  = Focal length, d = diameter of 
focus.
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vibrations along the beam propagation direction (longitudinal, or z direction) give rise 
to a pressure, p(z) and results in a particle velocity, u(z). Note that the particles have 
no net motion, they simply oscillate about a central position at a velocity given by u. 
The speed at which the wave front propagates is given by c, the speed of sound, values 
for which vary by tissue type. For water, cw = 1500 m /s, and this is a good approximate 
value for most soft tissues. The ratio of pressure and particle velocity defines a 
medium’s impedance, Z , which is also related to the density of the tissue, p, and the 
speed of sound by:
The beam will propagate through a medium with a wavelength, A, given by:
Thus a 1 MHz wave in water would have a wavelength of \=  0.15 cm. From these 




As the wave propagates through successive layers of tissue, several factors conspire to 
dissipate its energy, namely: (1) absorption, (2) scattering, (3) reflections off tissue 
interfaces. Absorption and scattering are usually combined into a single attenuation
coefficient, a, that varies by tissue type and is approximately linearly proportional with 
frequency. If a wave entering a block of tissue has initial pressure p0, and 
corresponding power density I0, then the remaining pressure and power after traveling 
a distance z through the tissue is:
p ( z ) = p 0e-az I(z) = I0e-2az (1-21)
In medical imaging applications it is desirable to use smaller wavelengths to improve 
the imaging resolution. However, Eqn (1.21) demonstrates the increased attenuation 
that results from higher frequencies will reduce the depth of penetration for a given 
power density. Using the same reasoning, when attempting to transmit focused 
ultrasound through the skull, lower frequencies are desirable because less loss occurs 
in the bone and regions deeper into the head become reachable. As will be seen later, 
the weakness of using larger frequencies for FUS is that it enlarges the focal spot.
Finally, reflections must be considered. Assume the situation in Figure 1.9
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Figure 1.9: Reflection and refraction of incident wave at interface between two tissue 
types.
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where a plane wave traveling in a medium with speed of sound cx and impedance Z1 
strikes a tissue boundary at an angle 6i relative to the normal of the boundary. Also, 
assume the second material has speed of sound c2 ±  c1 and impedance Z2 ±  Z 1. Some 
of the incident beam will be reflected at an angle dr = 6i and thus cannot contribute 
to the forward motion of the wave. The transmitted wave will be refracted as it passes 
through the boundary due to differences in the speed of sound of the materials. The 
angle of the transmitted wave is given by Snell’s law, which applies for ultrasound 
waves just as it does for electromagnetic waves:
A reflection coefficient, R, is defined as the ratio of the reflected (pr) and transmitted 
(pl) pressure waves for a given angle of incidence and transmission:
In this work, only small incident angles will be considered (6i = 6t & 0°), which 
reduces the previous equation to:
s in^  \ 1 c1
(1.22)sin dt X2 c2
R pr (z 2/cos 0t) -  (Z1/c°s e1)  
Pi (Z2/c° set) + (Z1/c°s °i)
(1.23)
~ Z2 - Z -  
= Z ^ + Z : (1.24)
Most often, the reflected power is of more interest than the reflected pressure. By 
computing the ratio of power densities we attain for the reflected wave:
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r n2 / z_
(1.25)
For the transmitted wave:
(1.26)
From these equations it is now possible to calculate the losses due to attenuation while 
traveling through a uniform tissue layer, as well as the reflected and transmitted power 
densities at a boundary between two tissue layers.
To generate selective and intense tissue heating, it is necessary to concentrate a 
transducer’s power density into a small volume, referred to in this work as the “focal 
spot.” Several methods exist to produce this focusing effect.
First, a single-element transducer can have a sonic lens placed in front of it, 
which, much like glasses correct human vision, causes the incident wave to be bent 
and focused to the desired focal distance. This method has the advantage that different 
lenses can be inserted to provide multiple focal distances with a single transducer. 
However, it is not optimal for FUS therapies since it cannot be changed quickly during 
a treatment and so mechanical positioning would still be necessary.
Second, the surface of a single-element transducer can be made in a spherical 
shape, which results in a natural focus (or geometric focus) determined by the radius 
of curvature (see Figure 1.8). This eliminates the need for a lens, but also fixes the focal
1.3.3 Beam Focusing and Transducer Types
position, and thus to reach multiple positions in the tumor, mechanical movement of 
the transducer would be needed.
Third, the surface of a spherically shaped transducer can be broken into many 
individually controllable elements. This is called a phased-array transducer and is the 
type of device used throughout this work. For a given radius of curvature, the single 
element transducer creates a geometric focus at the same location as the phase-array, 
however, the phased-array can dynamically adjust the location of peak intensity by 
altering the phase of the voltage that excites each element. This is referred to as 
electronic steering and does not require mechanical movement of the transducer. A 
variety of phased-array transducer designs exist with the number of elements ranging 
from 10s to 1000s.
The advantages of phased-array transducers has opened new possibilities for 
FUS that were not available to investigators in the 1940s. For starters, MR 
thermometry provides a remarkable noninvasive monitoring capability, but the 
movement of objects (such as a transducer), even if outside the imaging volume, can 
induce variations in the magnetic field experienced by the sample, corrupting the 
temperature maps. Furthermore, mechanical movement requires motors that tend to 
induce noise and artifacts in the MR images. Electronically steering the focal spot with 
a phase-array transducer avoids these issues, and complex trajectories can be achieved 
without motors. Transcranial transmission of ultrasound is another emerging 
application reinvigorated by phased-array technology. While nothing can be done to 
reduce the attenuation of the skull, the focal quality and amount of energy delivered 
to the target volume is degraded by variations in the skull’s thickness. With knowledge
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of the skull’s geometry derived from CT or MR imaging, the element phases can be 
adjusted to correct for these effects [15]. Phased-array transducers do introduce 
significantly more complexity to the electronics required to drive the system, and 
makes the system more costly. Also, power is lost to secondary grating lobes which 
can, depending on the design of the transducer, deposit significant energy outside the 
desired focal spot. This can be reduced by decreasing the spacing between elements to 
< A/2, but this can mean using a very large number of elements. Another strategy is 
to randomly position the elements such that they create fewer locations of secondary 
constructive interference.
The focal spot for ablative FUS transducers is usually ellipsoidal in shape, and 
the systems used in this work have a full width half max (FWHM) on the order of
2 x 2 x 8 mm at 1 MHz. For a spherical transducer, the pressure pattern at the focus is 
given by a first-order Bessel function of the first kind, and the diameter, d, of the focal 
spot can be computed from the first zeros of this function:
(1.27)
It can be seen that the width depends on the focal length, lf , and the transducer 
diameter, D, as well as the wavelength (see Figure 1.8). Thus lower frequencies (larger 
wavelengths) will increase the diameter of the focal spot.
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1.3.4 Heating Tissue with Focused Ultrasound
The amount of tissue heating generated by application of focused ultrasound 
depends on many parameters including: the transducer design, focal spot size, applied 
power, applied frequency, and tissue properties such as specific heat, density, and 
attenuation. While attenuation includes the combined effects of absorption and 
scattering, absorption is the dominant factor in most biological tissues. Therefore, 
energy lost due to attenuation is approximately the energy available to generate tissue 
heating. If the power density from Eqn (1.21) is differentiated with respect to a volume 
bz, the result is the following expression for the time-rate of energy deposition per unit 
volume, Q:
Sometimes a related quantity called the specific absorption rate (SAR) is used, and this 
is related to Q with:
Here, SAR has units of W /kg compared to Q units of W /m 3. Given the rate of energy 
delivery to the tissue, and the tissue’s specific heat, ch, the rate of temperature rise can 
be calculated from:
Q = —2 a l (1.28)
(1.29)




In reality, this will only apply at the start of a heating pulse as conduction will transfer 
heat to neighboring tissue and reduce the rate of heating. A more accurate and detailed 
thermal model commonly used is the Pennes bioheat transfer equation [16]; it accounts 
for conduction and perfusion losses. This model can be implemented on a computer 
but requires detailed knowledge of the tissue properties and their spatial distribution. 
Regardless, the rate of tissue heating can be on the order of 1-4 °C /s for FUS thermal 
ablation, and given common MR thermometry sampling intervals of 2 -  8 s, significant 
temperature change can occur within one temperature sample. This poses challenges 
for control of thermal therapies, a topic addressed in more detail in Chapter 2.
MR thermometry allows for the monitoring of tissue heating caused by FUS, 
however, a metric that relates temperature history to tissue damage is necessary to 
effectively treat cancerous tumors while preventing damage to healthy tissue. The most 
commonly used metric, and the one used throughout this dissertation, is the 




where T  is the temperature of the tissue in °C, and R _  2 when T  > 43 °C and R _  4 
when T  <43  C  . A thermal dose of 240 CEM43 is a conservative threshold for 
histological tissue damage. This is explored in more detail in Chapter 2.
1.4 MR Acoustic Radiation F orce Imaging
This section combines the MRI and ultrasound concepts discussed in Sections
1.2 and 1.3 to provide a description of how acoustic radiation force imaging (ARFI) 
can be measured using MRI. The benefits of performing MR-ARFI are discussed in 
Chapters 3 and 4. As ultrasound propagates through tissue, energy is lost due to 
absorption and reflections. Assuming a homogenous medium, reflections will be 
ignored. Given the time-average beam intensity, I , and the attenuation coefficient a, 
the resulting radiation force per unit volume, Ta is:
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r , , = 2 ^  (1.32)
This force causes the tissue to displace by a small amount, typically 1-30 |im 
depending on the applied power and tissue properties. To encode this displacement 
into the MR signal, a new set of gradients, called motion encoding gradients (MEG) 
are applied before the signal is readout. Many MEG schemes are possible, but a simple 
bipolar scheme is shown in Figure 1.10. If no displacement is present, as is the case 
when the ultrasound is off, then the first lobe of the MEG will add a phase to all spins 
which will be subsequently subtracted by the second lobe of the MEG. An entire set 
of k-space is acquired with ultrasound “OFF” and saved. Next, a measurement is 
acquired where a short burst of ultrasound (1 -  20 ms) is fired during only the second 
lobe of the MEG. In this case, the first lobe adds a phase, as before, however, spins 
that are displaced during the second lobe do not experience the same magnetic field 
they did during the first lobe, and thus a residual phase will remain in locations that
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Figure 1.10: Example timing diagram with ARFI motion encoding gradients. (a) 
When no US pulse is used the phase added by MEGa1 gets subtracted during MEGa2. 
(b) When US is fired during MEGA2, the phase added by MEGAi is not subtracted for 
tissue that was displaced by the US.
experienced displacement. When a motion encoding gradient of duration tenc is 
applied at an amplitude of Gmeg , then the tissue displacement, AD,  generates an 
accrued phase given by:
A 0a _  1 I GMEG(t)A D{t)dt 
0^
(1.33)
Similar to PRF thermometry, described in Section 1.2.9, A 0 a is derived from a 
complex phase subtraction performed between the reference image (with no 
ultrasound), and the image with ultrasound on. Since Gmeg is known, the phase 
difference can then be converted to a time-average displacement using:
A D _
l M E G Mom (1.34)
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where M EGMom is the gradient area set by the user in the MR pulse sequence.
It is necessary to synchronize the start of the ultrasound burst with the MEG. 
At the time this work was carried out, no hardware existed for doing so. Appendix A 
describes the design of a device to trigger the ultrasound from an optical trigger pulse 
emitted by the MRI.
1.5 References
[1] Z.-P. Liang and IEEE Engineering in Medicine and Biology Society, Principles of 
magnetic resonance imaging: a signal processing perspective. Bellingham, Wash. : New 
York: SPIE Optical Engineering Press; IEEE Press, 2000.
[2] D. G. Nishimura, Principles of magnetic resonance imaging, 1.1 ed. Stanford 
University Press.
[3] C. P. Slichter, Principles of magnetic resonance, 3rd ed. Berlin; New York: Springer, 
1996.
[4] E. M. Haacke, Magnetic resonance imaging: physical principles and sequence design. 
New York: Wiley, 1999.
[5] D. L. Parker, V. Smith, P. Sheldon, L. E. Crooks, and L. Fussell, “Temperature 
distribution measurements in two-dimensional NMR imaging,” Med. Phys., vol. 
10, no. 3, pp. 321-325, Jun. 1983.
[6] D. L. Parker, “Applications of NMR imaging in hyperthermia: an evaluation of 
the potential for localized tissue heating and noninvasive temperature 
monitoring,” IEEE Trans. Biomed. Eng., vol. 31, no. 1, pp. 161-167, Jan. 1984.
[7] Y. Ishihara, A. Calderon, H. Watanabe, K. Okamoto, Y. Suzuki, K. Kuroda, 
and Y. Suzuki, “A precise and fast temperature mapping using water proton 
chemical shift,” Magn. Reson. Med., vol. 34, no. 6, pp. 814-823, Dec. 1995.
[8] J. De Poorter, C. De Wagter, Y. De Deene, C. Thomsen, F. Stahlberg, and E. 
Achten, “Noninvasive MRI thermometry with the proton resonance frequency 
(PRF) method: in vivo results in human muscle,” Magn. Reson. Med., vol. 33, no. 
1, pp. 74-81, Jan. 1995.
[9] D. A. Christensen, Ultrasonic bioinstrumentation. New York: Wiley, 1988.
[10] S. L. Hagen-Ansert, “Society of diagnostic medical sonographers: a timeline of 
historical events in sonography and the development of the SDMS,” J. Diagn.
38
Med. Sonogr., vol. 22, no. 4, pp. 272-278, Jul. 2006.
[11] J. G. Lynn, R. L. Zwemer, A. J. Chick, and A. E. Miller, “A new method for the 
generation and use of focused ultrasound in experimental biology,” J. Gen. 
Physiol., vol. 26, no. 2, pp. 179-193, Nov. 1942.
[12] J. G. Lynn and T. J. Putnam, “Histology of cerebral lesions produced by focused 
ultrasound,” Am. J. Pathol., vol. 20, no. 3, pp. 637-649, May 1944.
[13] W. J. Fry, J. W. Barnard, E. J. Fry, R. F. Krumins, and J. F. Brennan, 
“Ultrasonic lesions in the mammalian central nervous system,” Science, vol. 122, 
no. 3168, pp. 517-518, Sep. 1955.
[14] W. J. Fry, W. H. Mosberg, J. W. Barnard, and F. J. Fry, “Production of focal 
destructive lesions in the central nervous system with ultrasound,” J. Neurosurg., 
vol. 11, no. 5, pp. 471-478, Sep. 1954.
[15] A. Kyriakou, E. Neufeld, B. Werner, M. M. Paulides, G. Szekely, and N. Kuster, 
“A review of numerical and experimental compensation techniques for skull- 
induced phase aberrations in transcranial focused ultrasound,” Int. J. 
Hyperthermia, vol. 30, no. 1, pp. 36-46, Feb. 2014.
[16] H. H. Pennes, “Analysis of tissue and arterial blood temperatures in the resting 
human forearm,” J. Appl. Physiol., vol. 1, no. 2, pp. 93-122, Aug. 1948.
[17] S. A. Sapareto and W. C. Dewey, “Thermal dose determination in cancer 
therapy,” Int. J. Radiat. Oncol., vol. 10, no. 6, pp. 787-800, Apr. 1984.
CHAPTER 2
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FOR MAGNETIC RESONANCE GUIDED 
FOCUSED ULTRASOUND THERAPY
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2.1 Introduction
Magnetic resonance image-guided focused ultrasound (MRgFUS) is a 
promising noninvasive and radiation-free treatment modality that has been used to 
treat illnesses ranging from several types of cancer [2]-[9] to neurological disorders 
such as essential tremor [10]. In cancer therapy, MRgFUS has the advantage, 
compared to radiation therapy and chemotherapy, that dose delivery can be monitored 
during treatment and its effects on tissues can be observed relatively quickly.
While heating a tumor to sufficiently high temperatures will induce tumor 
necrosis, doing so accurately, with no collateral damage to normal tissue, and within 
practical treatment times is a major concern [3], [11]. Such time concerns are present 
in current FDA approved treatments of uterine fibroids [12] and will become 
increasingly prevalent when large malignant tumors located near critical tissues are
treated due to the enhanced need for dose delivery accuracy and normal tissue safety 
-  both of which lead to slower treatments. Thus, it is critical to deliver thermal dose as 
time-efficiently as possible, and this can only be achieved using both computerized 
control systems designed specifically to minimize treatment times and protect critical 
tissues, and optimal treatment planning.
Early investigations into treating large tumors with focused ultrasound 
optimized a series of sequential, point-by-point, sonications [13]-[15]. Because their 
focal zones were much smaller than the tumor, many focal positions were required, 
and it was concluded that to protect healthy tissues in the transducer’s near-field, a 
cooling period of 30-90 s must be inserted between every 5-20 s heating pulse [3], [11]. 
Such cooling periods allowed each successive pulse to be initiated at the same basal 
condition, thus providing for more uniformly applied heating pulses. However, such 
interpulse delay resulted in long treatments and the optimal delay that avoided normal 
tissue damage varied for each scenario.
Many temperature controllers have been introduced for hyperthermia to better 
account for the variability in heating in vivo tissues [16]-[19], with an emphasis on 
creating and maintaining a small, uniform temperature elevation over a large region. 
These were feedback controllers that required a priori knowledge for tuning, and their 
stability could be compromised if the control parameters were improperly tuned or if 
they changed during treatment. Other temperature controller work has sought to 
circumvent the interpulse cooling period in focused ultrasound surgery (FUS) 
treatments by increasing the volume heated via rapid switching of the focal zone 
among several locations [20]-[24]. Using multiple foci or rapid phased array steering
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effectively defocuses the focused ultrasound beam; thus, trading increased heated 
volume for decreased heating speed. Such multipass (or volumetric) heating strategies 
have been combined with magnetic resonance temperature imaging (MRTI) feedback 
to make controllers that seek to optimize a fixed treatment trajectory, such as spiral 
trajectories [20]-[22], and concentric circles [23], [24]. These volumetric heating 
strategies have demonstrated that MRgFUS can create consistent ablation regions in 
vivo, and they have the advantage of being easier to control with currently achievable 
MRTI sampling intervals because they raise the temperature of tissues more slowly. 
However, these controllers are constrained to a single volumetric ablation strategy, 
and rely on high acoustic power to achieve acceptable treatment times [23], and thus 
may not be appropriate for all tumor geometries or locations. The ability to conform 
the heated region to the target tissue geometry has successfully been shown in catheter- 
based systems [25]-[27], and this spatial temperature control improved the specificity 
of the ablated region. However, all of the aforementioned controllers have focused on 
controlling temperature, not thermal dose, and no direct protection for healthy tissues 
was provided.
Therefore, unmet needs exist, especially in the area of time-optimal control of 
thermal dose that ensures safety for critical normal tissues and that can accurately 
conform thermal dose delivery to an arbitrary shape. The adaptive model-predictive 
controller (AMPC) presented here addresses these needs primarily by augmenting the 
MRTI measurements with model-based predictions of the future temperatures and 
thermal doses to be delivered during both heating and cooling periods. Using model- 
prediction, the AMPC reduces treatment times by anticipating thermal dose that will
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be delivered to the tissue in the future, thereby increasing the accuracy of dose delivery 
and decreasing the dose delivered to healthy tissues. Unlike temperature controllers, 
the AMPC is concerned with controlling thermal dose, and because of the highly 
nonlinear accumulation of dose with temperature, model-prediction is critical to 
delivering the target dose as quickly and accurately as possible. The controller by 
Arora et al. [28] also controlled thermal dose using model-prediction, however that 
controller was restricted to 1D tumors and the model’s complexity required a priori 
knowledge, which would be difficult or time consuming to acquire clinically. The 
present AMPC is substantially different from previous work as it identifies and 
dynamically adapts the heating model during treatments, making the controller 
practical for treatments with any number of sonication points. This also makes its 
predictions robust to changes in tissue properties that may occur during treatment and 
eliminates the need for lengthy pretreatment model identification. Furthermore, the 
AMPC does not require any parameter tuning or a priori knowledge of tissue 
parameters.
To ensure treatment safety, two factors are critical: 1) the controller must have 
a means for protecting healthy tissues, and 2) the controller must monitor a sufficiently 
large region surrounding the treatment volume and the transducer’s beam path for 
undesired heating (for example, in the transducer’s near field [29], [30], or because of 
reflections from tissue-bone interfaces [6], [31], [32]). To address the first safety factor, 
the controller enforces configurable temperature constraints on tissues selected by the 
clinician thus providing a direct mechanism to limit, or eliminate, undesired dose 
delivery in a flexible manner that can favor safety over speed, or vice versa, at the
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clinician’s discretion. Moreover, this explicit safety feature is enhanced by the model- 
prediction feature which implicitly reduces normal tissue dose by reducing heating 
times. The second safety factor motivates the use of 3D MR imaging that delivers 
temperature measurements to the controller with high spatial resolution and a large 
field-of-view (FoV) [33], [34]. However, both of these imaging requirements 
accentuate an existing drawback of MR temperature imaging, that of a relatively long 
interval between measurements (1-8 s). Without model-prediction, the highly 
nonlinear nature of thermal dose combined with long measurement intervals makes 
accurate measurement and control of thermal dose difficult; the AMPC helps alleviate 
this problem by supplementing model-predicted temperature and thermal dose 
estimates between MRTI measurements.
Finally, the controller presented here will optimize heating times along any 
path selected and is not limited to spirals, circles or lines, thus allowing the ablated 
volume to be conformed to the shape of the target. During therapy, the clinician retains 
full supervisory control while leveraging a computer’s ability to rapidly monitor and 
adjust many parameters simultaneously.
The AMPC was tested in vivo, and simulations were used to evaluate the 
tradeoffs among competing controller parameters, to demonstrate the controller’s path 
independence, and to evaluate how model-prediction affects treatment time and the 
accuracy of thermal dose delivery.
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2.2 Materials and Methods
2.2.1 Controller Design
2.2.1.1 Overview
The adaptive model-predictive controller has the potential to facilitate 
treatments that are fast, reliable, and safe, and it supports clinicians by automating 
tasks that are difficult and time consuming for humans. The controller’s central goal 
is to automatically deliver a target thermal dose to a defined target tissue volume as 
quickly as possible while simultaneously safeguarding critical tissues. The clinician 
provides overall treatment supervision beginning with identification of two classes of 
voxels on the patient’s anatomical MR images: (1) treatment voxels (TVs) to be treated 
to a target thermal dose, and (2) protected voxels (PVs) to be safeguarded by limiting 
their maximal temperatures.
Figure 2.1a shows a simple example with nine treatment voxels and 14 
protected voxels; voxels not assigned (NA) to either class require neither ablation nor 
protection (e.g., tumor margin or other noncritical tissues). A treatment is completed 
once all TVs have received their target thermal dose (TD) as measured in cumulative 
equivalent minutes at 43°C (CEM43 ) [35], given by:
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(2 .1)
where T  is the voxel’s MR-measured temperature, and R = 2 when T  > 43°C or R = 
4 when T  < 43°C. In this work, the small thermal dose that accrues below 42°C was 
neglected. A target dose of 240 CEM43 was used throughout this study, as this is a
















Figure 2.1: Three example controller treatment plans for a simplistic treatment, (a) MRI slice of patient taken perpendicular to 
the ultrasound beam-axis, on which the clinician identifies nine treatment voxels (TVs) and 14 protected voxels (PVs). The 
clinician groups TVs into cells (with each cell containing one or more TVs). During treatment, each cell is ablated sequentially as 
a “minitreatment” using a clinician-selected focal zone trajectory, (b) Plan 1 -  single-pass heating: example of one extreme (one 
TV per cell) where the tumor is broken into nine treatment cells (number outlined in red at top left), each with only a single TV. 
Each cell is ablated while the focal zone is stationary at the circled location for the cell. The first number within each circle 
indicates the associated treatment cell of the focal position, while the second indicates the ordering of focal positions within the 
cell. For example, treatment of the first cell begins with the focal zone dwelling at position 1:1 until the controller’s model predicts 
that the cell’s single TV has been sufficiently heated, at which time treatment advances to the second cell (focal zone dwelling at 
location 2:1), and so on until finally reaching the ninth cell with the focal zone dwelling at location 9:1. (c) Plan 2 -  multipass 
(volumetric) heating: the opposite extreme (all TVs in one cell) where all TVs are assigned to a single treatment cell that is ablated 
by repeatedly scanning the focal zone through positions 1:1, 1:2, ..., 1:9, until the controller predicts the entire cell is treated, 
(d) Plan 3 -  example of one possible treatment plan between the two extremes of Plans 1 and 2. The tumor is broken into three 
treatment cells, each of which is assigned three treatment voxels. Treatment begins with the focal zone stationary at 1:1 until all 
three TVs in its associated cell are predicted to receive their target dose, at which point the controller repeats the heating process 
for the second cell by moving the focal zone to location 2 :1, and so on until all three cells are treated.
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commonly used conservative threshold for histological tissue damage [36]-[39]. 
However, some tissues can be damaged at lower thermal doses [40] and the user is free 
to set the target dose that best suits their application. When calculating thermal dose, 
the controller assumes a linear temperature change between the discrete MR 
temperature measurements.
Many tumors will consist of a large number of TVs, so to provide flexibility in 
implementing their preferred treatment plan, clinicians divide the tumor into treatment 
cells (with each cell containing one or more treatment voxels) during pretreatment 
planning. The controller sequentially ablates each treatment cell as part of a series of 
individual minitreatments, and will heat each cell for the minimum time predicted for 
all of its treatment voxels to reach the target dose by the end of the treatment. The 
treatment plan parameters that must be specified are summarized in Table 2.1, while 
Figures 2.1b-d illustrate three example controller treatment plans for a simple 
treatment. Note that the applied transducer power is fixed during treatment, and that 
automated algorithms can greatly simplify treatment plan setup once a high-level 
treatment strategy (i.e., single-pass, multipass, etc.) is selected by the clinician. 
Regardless of the treatment plan, the controller’s model anticipates the future dose to 
be delivered to each cell after the focal zone moves to subsequent locations. This 
feature allows the controller to advance to the next treatment cell before all of the TVs 
in the current cell reach their target thermal dose, thus saving time.
MRTI allows the controller to monitor the TVs’ and PVs’ temperatures at 
discrete times during treatment and determine: (1) if the temperature of any PV has 
exceeded its specified safety limit, at which time the controller turns off the ultrasound
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Table 2.1: Summary of treatment plan parameters
Treatment Plan Parameter Normally Specified By Clinician1, Automatically^
Classifying regions as TVs or PVs
High-Level Treatment Strategy
(single vs multiple pass, path type,
starting location, focal point spacing)
Number of Treatment Cells
Sequential Ordering of TC’s
Assignment of TVs to Treatment Cells
Safety temperature thresholds: TON & TOFF
Cooling Model Parameters
Heating Model Parameters
US Power Level (constant)
Parameters that can only be assigned by a clinician. fParameters that could be 
assigned automatically by an algorithm. TV = Treatment voxel, PV = Protected 
voxel, TC = Treatment Cell.
power; and (2) if all TVs in the cell have reached their desired switching dose (see 
below), at which time the controller begins heating the next cell.
2 .2 .1.2 Treatment voxel model prediction
A real-time 3-D controller requires computationally efficient models so that 
predictions can be completed in a fraction of the temperature sampling interval. Thus, 
the AMPC uses a simple, flexible, exponential heating and cooling model for each 
treatment voxel, as follows:
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Theatz(t) = A l + B l ( l - exp
(2 .2)
Tcooift) = C ,-  D;exp
here i indicates the i-th treatment voxel, A i is the initial temperature before heating, 
is the final temperature after cooling, Bl and Dl are the overall temperature changes 
associated with heating and cooling, respectively, and th and tc are the exponential 
time constants for heating and cooling, respectively. A i is obtained dynamically from 
the temperature measurements, while Cl is set to 37 °C for all voxels as a conservative 
estimate. The heating terms Bl and th can be estimated before beginning the 
treatment and are subsequently derived and adapted during treatment as each new set 
of temperature measurements arrive. The cooling parameter Dl is updated 
dynamically by subtraction of from the peak temperature measured during heating, 
while Q  and rc are set in advance by the clinician and fixed during treatment.
To minimize treatment time, the controller uses the model to anticipate three 
aspects of the future temperatures of the TVs in the active treatment cell: (1) heating 
time prediction -  the heating time remaining for the TVs to reach their switching dose;
(2) cooling dose prediction -  the TVs’ temperatures, and concomitant thermal doses, 
predicted to occur during the period when the controller has advanced the focal zone 
to subsequent treatment cells, and; (3) peak temperature prediction -  the peak 
temperature that each TV will reach at the time when heating of the current cell ends. 
These three model-based anticipation features allow the heating power to be moved to 
the next cell earlier than it would be otherwise, thus minimizing heating time and,
most importantly, the amount of concurrent heating of protected tissues.
2.2.1.2.1 Heating time prediction. This feature iteratively calculates the shortest 
heating time remaining such that all TVs in a treatment cell will reach their target dose 
by the time the tissue has cooled to < 42°C. Note that a TV’s switching dose, the 
thermal dose delivered at the time the heating of a cell ends, is less than the TV’s target 
dose because the cooling prediction (described below) is performed at each iteration. 
Heating time prediction also saves time by allowing the controller to switch from one 
cell to the next between MRTI measurements since for a given MRTI sampling 
interval (e.g., 5 s), it frequently occurs that a cell’s TVs will all have reached the 
switching dose just after one temperature measurement has been made (e.g., 1 s after). 
Thus, if prediction were not being used, and so the controller waited until the next 
measurement arrived before advancing to the subsequent cell, 4 s of unnecessary 
heating would have been applied, thereby over-treating the tumor (not detrimental) 
but, more seriously, unnecessarily heating the protected voxels. While not necessarily 
a concern for a single heating pulse, the effect in the normal tissue is cumulative due 
to overlap of the SAR pattern in the near-field. This feature can reduce the penalties 
incurred when increasing the MRTI sampling time, which can in turn improve 
temperature measurement precision, increase field-of-view, or improve spatial 
resolution.
2.2.1.2.2 Cooling dose prediction. The cell’s TV temperatures and thermal doses 
are predicted for the future time period after the controller has advanced the focal zone 
to the next treatment cell. Again, this allows the controller to move to the next 
treatment cell earlier rather than waiting for the entire target dose to be delivered
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during the heating period.
2.2.1.2.3 Peak temperature prediction. This feature is activated once the heating 
time prediction mode schedules the transition to the next cell. When a cell is heated 
for only part of an MR acquisition interval, the peak temperature of the TVs may not 
be measured by MRTI, which could result in an underestimate of the true thermal 
dose delivered. This is important due to the strong nonlinearity of thermal dose that 
results in large doses being delivered in very short times at high temperatures. The 
controller corrects for this by supplementing the discrete MRTI measurements with 
continuous, model-predicted TV temperatures up to the switching time. This improves 
knowledge of the actual dose delivered and mitigates the effects of longer MRTI 
sampling durations.
The computational simplicity of this model allows the controller to rapidly 
adapt the heating model of each TV in the active cell after receiving a new set of MRTI 
measurements. Consequently, any changes to the tissue environment that impact the 
rate of heating (e.g., increased or decreased blood flow or changes in ultrasound 
attenuation) will automatically be taken into account. Furthermore, because the 
heating model is continuously updated during treatments, its predictions need only be 
accurate until the next measurement is received, not for the entire heating duration. 
Adaptation (updating of parameters in Eqn. 2.2) is performed by a constrained least- 
squares error fit, using Matlab’s fmincon function, to at least, the last Nmill 
measurements and at most, the last Nmax measurements since heating began in the 
current cell. Both N mill and N mx are user specified parameters, but for this study 
setting NmiD = 2 and N  max = 3 was found to identify accurate models. If the MRTI
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sampling rate is slow relative to the heating rate, so that the heated cell gets fully treated 
before NmiD MRTI samples are acquired (N < Nmin), then a model cannot be 
dynamically identified. In this case, the controller will make predictions based on an 
initial-guess model, if provided, until a model can be identified dynamically (N > Nmin), 
or in the last resort, it will disable heating-prediction. From the perspective of 
minimizing heating time, this is a drawback. However, this is not a problem from the 
point of view of delivering the target dose because the controller is monitoring the 
thermal dose accrued in all TVs, and thus at the next MRTI measurement it will detect 
that the target dose has been achieved and advance to the next cell. The simplicity of 
the exponential model is also advantageous because it minimizes the need for a priori 
knowledge of tissue properties or for pretreatment parameter identification, thus 
reducing the patient’s and clinician’s time spent in the MR facility.
2.2.1.3 Protected voxel safety
The controller safeguards protected voxels by enforcing a pair of user- 
configurable temperature constraints: TOFF and TON. The controller disables the 
ultrasound beam (triggering a cooling period) when the temperature of any PV exceeds 
Toff, and resumes heating once all PVs are below Ton. Each PV can be assigned 
unique constraint temperatures; for example, to more rigorously protect a particular 
area. Using temperature constraints is a conservative and flexible approach for limiting 
patient pain and protecting against tissue damage due to thermal dose. The effect of 
increased treatment safety on treatment time was examined in simulations.
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2.2.1.4 Additional controller features
The AMPC has several additional noteworthy features. First, measurement is 
given priority over prediction; i.e., if the heating model has under-predicted the actual 
thermal dose delivered during a measurement interval, and the next measurement 
confirms that all of the cell’s treatment voxels have actually received their target dose, 
the controller disregards the prediction and begins treatment of the next cell. Second, 
the controller continuously monitors and updates the thermal dose of all voxels in the 
imaging volume so if the heating of a given cell is interrupted by a safety violation, but 
the cell reaches its target dose during the subsequent safety-triggered cooling period, 
the controller will automatically advance to the next cell once the PVs reach Ton. 
Finally, as a “fail-safe” measure, if any TVs have not reached their target dose by the 
end of the treatment, then the controller will perform a “clean up” pass to deliver any 
missing dose.
2.2.2 Simulations
All simulations treated a cylindrical tumor of radius 7 mm and height 10 mm 
(1539 TVs) positioned in the center of a homogenous 10 x 10 x 10 cm tissue volume 
(Figure 2.2a) with a finite-difference grid resolution of 1 x 1 x 1 mm. A 4 x 4 x 3 cm 
volume of protected voxels (50,430 PVs in total) was identified starting at the 
ultrasound beam’s plane of entry into the simulated volume and extending 3 cm into 
the volume, leaving 1.5 cm of unassigned “tumor margin” voxels between the PVs and 
the bottom edge of the tumor (Figure 2.2b). The simulated transducer was a 256- 
element phased-array operating at 1 MHz (focal distance of 13 cm, aperture diameter 
of 14.5 cm, f-number = 0.90). The transducer was positioned in water 8 cm from the
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Figure 2.2: Configuration of simulation volume. (a) The ultrasound beam propagates 
through 8 cm of water before entering the 10 x 10 x 10 cm tissue volume of muscle 
with a cylindrical tumor centered within it. (b) Zoomed-in view of the tumor and 
protected voxels shown in (a). The tumor, (radius = 0.7 cm, height = 1 cm) is 
subdivided into three planes, which are visited in the order (M) middle (z = 0 mm, 
geometric focus), (B) back (z = +3 mm), (F) front (z = -3 mm).
simulated volume.
Two single-pass treatment plans (Figure 2.3) were simulated: (1) single pass- 
hottest neighbor (SP-HN) and (2) single pass-square spiral (SP-SS). For both treatment 
plans, the trajectories shown in Figure 2.3 were replicated in each of three planes 
shown in Figure 2.2b. Treatment progressed in axial “stacks,” each of which consisted 
of a single treatment cell from each plane, with the three cells in each stack ablated in 
the order: middle (z = 0 mm), back (z = +3 mm), front (z = —3 mm). There were 
149 treatment cells per plane (447 cells total), yielding an average of ~3.4 TVs/cell.
While the two treatment plans have the same number of cells, focal positions, 
and average number of TVs per cell, they differ in the sequence in which the cells are 
treated. The hottest-neighbor treatment plan takes advantage of the adjacency of 
successive axial stacks and the thermal buildup resulting from the superposition of 
SAR patterns from the most recently heated cells. The square-spiral initially shares 
some of that adjacency, and also takes advantage of thermal buildup in the tumor by 
proceeding sequentially from the center of the tumor to its periphery; however, as 
treatment progresses its treatment cells become increasingly farther apart and more 
independent from its recently heated predecessor cells.
The hybrid angular spectrum ultrasound simulation method [41] was used to 
efficiently precompute the 447 SAR patterns for each focal zone position required for 
each plan. The simulated SAR patterns were used in conjunction with Pennes’ bio­
heat transfer equation [42], in which the metabolic power generated by the tissue was 
neglected, the specific heat of the tissue and arterial blood were assumed to be 
approximately equivalent, and conduction and perfusion were assumed to be scalars,
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Figure 2.3: Middle plane (M) for the two simulated treatment plans: (a) single pass- 
hottest neighbor (b) single pass-square spiral; Gray = treatment voxels; Red outline = 
treatment cell; Black dot = focal zone position for a cell. The starting focal zone 
location is marked with a white star, while the ending location is marked by a white 
square. The focal zone dwells at each location until the associated cell’s treatment is 
completed. Note: although not visible in this drawing, each treatment cell includes 
multiple TVs (~3.4 on average) that extend in the direction perpendicular to the slice 
shown.
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leading to the simplified equation:
ptc , iT{X' ^ Z' t) = Qa(x,y , z , t )  + kV 2T  — w,,ct (T — Tb) (2,3)
where T  is the tissue temperature in °C; x, y, z are the spatial coordinates in m; t is 
time in s; pt is the tissue density in kg/m3; ct is the tissue’s specific heat in J/kg/°C; 
Qa is the absorbed ultrasound power per unit volume in W /m 3 ; k is the tissue’s thermal 
conductivity in W /m/°C; wb is the blood perfusion rate in kg/m3/s, and Tb is the 
temperature of the blood in °C. Tb and all boundaries were set to the volume’s initial 
temperate, T0 = 37 °C. An explicit finite-difference solution (Euler’s method) was 
used to update temperatures between two time periods, Tl+1 and Ti, separated by At. 
For each time step, the simulation used one precomputed Qla pattern scaled to the 
desired power magnitude. Arbitrary focal zone trajectories can be simulated by 
successively changing the Qla pattern for each corresponding time step. The simulation 
time step was = 0.1 s except when the controller’s predicted heating time was not 
evenly divisible by A t (e.g., 0.25 s), in which case a single shorter time step equal to 
the remainder (e.g., 0.05 s) was used for the last time step.
The MR sampling interval A t MR is the duration required to acquire each MR 
temperature measurement. While the finite difference thermal model operates at A t 
to ensure numerical stability, the controller is only given temperature information 
every A tMR. Furthermore, at the i-th M R measurement, the center of k-space is 
usually sampled at the midpoint of the sampling interval, i.e., at t m . = A t MR(i — 0.5),
thus the temperature reported at the end of an interval, te . = i- A t MR , is most 
indicative of the tissue temperature at tm . Effectively, the controller is making 
decisions at t based on measurements at tm , a delay of At™R, and this real-world 
effect is included in the simulations.
The following tissue properties were assigned to all voxels; these values fall 
within published ranges for biological tissues [43], [44]: US attenuation = 0.05 
Np-cm-1-MHz-1, speed of sound = 1517 m-s-1, pt = 993 kg-m-3 , k = 0.58 W-m-1-°C-1, 
ct = 4187 J-kg-1-°C-1, wb = 0.5 kg-m-3-s-1 . Unless otherwise noted, simulations used: 
M mr = 3.0 s, Toff = 43.0 °C, Ton = 41.5 °C, and an applied power of 15 W. At this 
power, the resulting max/min peak absorbed power densities in the treatment cells 
were 1.97 x 107 /  1.46 x 107 W-m-3, which correspond to linear heating rates of 4.7 /
3.5 °C-s-1.
To quantify the time savings derived from each of the major controller 
optimization features, simulations were performed at successively increasing levels of 
optimization, with each level keeping the features of the previous level and adding one 
more optimization feature. As a reference case, the independent heating pulses (IP) 
scenario was run first without any AMPC features. For this case, each cell begins at a 
baseline temperature of 37 °C and the cell’s entire 240 CEM43 target dose is delivered 
during the heating period. Next, the different AMPC optimization levels were enabled 
as follows: (1) +temperature buildup: this first level of optimization illustrates the 
simplest benefit of using MRTI to monitor the TVs’ temperatures. Rather than 
beginning at the baseline temperature of 37 °C (as in the IP reference case), the cell’s 
TVs begin at the final temperatures reached after treating the previous cell. As in the
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IP case, each cell receives 240 CEM43 and only the dose delivered while heating that 
cell is considered (i.e., no prior dose was accounted for, and the future dose to be 
delivered after the focal zone advanced to the next cell is ignored). (2) +Prior dose: 
adding this feature to the temperature buildup feature demonstrates the benefit of using 
a computer that can use MRTI to calculate the thermal dose delivered to the volume 
in real-time. When treatment of a new cell begins, the dose already delivered to that 
cell’s TVs is known, and thus the controller need only deliver the remaining dose. (3) 
+Adaptive model-predictive control: this level adds the three predictive modes of the 
AMPC (described previously) to the use of temperature buildup and prior dose 
accounting.
In the IP reference case, only the three cells with focal zone positions along the 
transducer centerline at x = y  = 0, z = {0 mm, -3 mm, +3 mm} were simulated. The 
time to treat each of these three cells was multiplied by the number of cells in each z- 
plane (149) and summed to arrive at the total treatment time. This represents the 
minimum treatment time achievable by the independent heating pulses approach (for 
a given transducer power) since it ignores the inherent power losses when using 
phased-array steering to treat the edges of the tumor. These losses would reduce the 
SAR and thereby lengthen the needed heating times. All simulations were run first 
with safety constraints disabled, and again with safety constraints enabled 
(Ton = 41.5 °C and Toff = 43.0 °C).
2.2.3 In Vivo Experiments 
After completing development tests in phantoms, the AMPC was tested in vivo 
in rabbit thigh muscle (two rabbits, three thighs) with a target dose of 240 CEM43 in all
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treatment voxels. Experiments were designed to test specific features of the controller. 
In all tests, the rabbit was positioned on its side (Figure 2.4a) approximately 11.5 cm 
above the transducer, which was driven by electronics from Image Guided Therapy 
(Pessace, France). The transducer (described in the previous section) was coupled to 
the rabbit with deionized water that was degassed using a custom built degassing 
system. Measurements from a Hanna Instruments HI-9146 (Woonsocket, Rhode 
Island, USA) meter confirmed that this system degassed the water to a dissolved 
oxygen level of < 1.0 mg/L of water.
In order to demonstrate the controller feature that allows it to assign different 
numbers of TVs to each treatment cell and then automatically treat them in sequence,
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Figure 2.4: Configuration of in vivo experiments. (a) Rabbit’s position during all 
controller tests. (b) Anatomical MR image of in vivo rabbit experiment in the transverse 
(left) and coronal (right) planes, respectively. White box indicates approximate 
treatment location for Run 1. (c) Controller configuration: single-pass-raster scan 
treatment plan with nine treatment cells covering a 5 x 5 x 3 mm volume. Each cell 
was heated by a single focal zone position (circles). Shading and outlines indicate to 
which cell each treatment voxel was assigned.
the controller was configured to treat a 5 x 5 x 3 mm treatment volume using a single­
pass raster-scan treatment plan in a single plane, as shown in Figure 2.4b. The 25 
treatment voxels were assigned to nine treatment cells, and each cell was sequentially 
ablated by dwelling at a single focal zone position. Controller Runs 1-4 used a 
transducer power of 20 W and had no normal tissue constraints, while Run 5 used a 
transducer power of 33 W and had a 16 x 16 x 3 mm region of protected voxels 
specified in a plane 2 cm below the treatment volume with TOFF and TON thresholds of 
45 °C and 41 °C, respectively. Each run was performed in a unique region of rabbit 
thigh that had not been ablated by previous tests, and a single short test shot was 
performed in advance of each run to adjust the targeting of the center cell.
Temperature measurements for controller feedback were acquired using a 
Siemens 3T Tim Trio MRI scanner and a segmented gradient recalled echo (GRE) 
echo planar imaging (EPI) proton resonance frequency shift (PRF) thermometry 
sequence with fat saturation. For Runs 1-4, 3D temperatures were acquired every 4.2 
s in a 256 x 168 x 27 mm volume at 2 x 2 x 3 mm voxel resolution, and each 
measurement was zero-fill-interpolated to a voxel spacing of 1 x 1 x 1.5 mm to reduce 
partial volume effects [45]. Other relevant MR parameters were: TR/TE = 35 /  11 ms; 
flip angle = 15°; EPI factor = 9; 18 slices with 33.3% slice over-sampling; and 
bandwidth = 738 Hz/pixel. For Run 5, the PRF sequence was run with three 2D slices 
(two in the tumor, one in the protected tissue) in order to cover a sufficiently large 
field-of-view to monitor the protected voxels; relevant MR parameters for this 
sequence were: FoV = 256 x 176 mm; resolution = 2 x 2 x 3 mm (zero-fill-interpolated 
to 1 x 1 x 3 mm); TR/TE = 39/8 ms; flip angle = 25°; EPI factor = 1; bandwidth = 751
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Hz/pixel; acquisition time = 3.7 s.
2.3 Results
2.3.1 Simulations
2.3.1.1 T reatment plan independence
To illustrate the controller's treatment plan independence, both treatment plans 
shown in Figure 2.3 were simulated at 15 W with and without safety constraints, and 
the resulting treatment time and maximum thermal dose delivered to the protected 
tissue are shown in Figure 2.5. With safety constraints disabled, the single pass-hottest 
neighbor plan was 17% faster than the single pass-square spiral plan (15 vs 18 
minutes), and also reduced the maximum dose delivered to the protected voxels by 
44% (282 CEM43 vs 500 CEM43). For the practical case when safety constraints were 
enabled, the single pass-hottest neighbor plan was again faster than the single pass- 
square spiral plan (1 hour 45 minutes vs 2 hours 5 minutes), however, both plans were 
approximately 6-7 times slower than their unsafe cases. Importantly, however, the
Figure 2.5: Treatment time and maximum protected voxel thermal dose as a function 
of treatment plan at 15 W. AMPC was used for all runs. SP-SS = single-pass-square- 
spiral, SP-HN = single-pass-hottest neighbor.
protected voxel dose was limited to < 27 CEM43 for the single pass-hottest neighbor 
plan and < 35 CEM43 for the single pass-square spiral plan.
Unless otherwise noted, the remaining simulations only consider the single 
pass-hottest neighbor treatment plan because it was 24% faster than the single pass- 
square spiral plan and delivered 23% less dose to the protected tissues.
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2 .3 .1.2 Time savings derived from controller optimization levels
The treatment times and maximum protected voxel thermal dose resulting as 
each of the major controller optimization features are enabled are shown in Figure 2.6. 
The no-constraint half of this graph shows the time gains attainable by successively 
adding controller optimizations; however, all of those results yielded thermal doses in 
the protected voxels that exceeded the target dose for tumor ablation. For example, 
the +thermal buildup (+TB) case without safety constraints delivered >3000 CEM43 to
IP +TB +PD +AMPC +AMPC +PD +TB
Figure 2.6: Treatment time and maximum dose delivered to protected voxels for the 
single pass-hottest neighbor treatment plan at 15 W as a function of optimization 
feature when PV safety constraints are disabled (shaded region) and enabled (white 
region). IP = independent heating pulses (no optimization); +TB = thermal buildup 
added; +PD = prior dose added; +AMPC = adaptive model-predictive control added. 
The maximum PV dose for +TB with no safety constraint is 3277 CEM43.
the protected tissues. Thus, the no-constraint cases are of interest only to illustrate the 
importance of considering safety.
In the practical case when safety constraints are enabled, treatment time 
sequentially decreases as each optimization level is added. Enabling temperature 
buildup gives a treatment time of 3 hours 52 minutes, almost as fast as the independent 
pulses case without safety constraints (note that the IP case is artificially fast since it 
does not include the interpulse cooling period, often 90 s, that would be necessary to 
make the pulses truly independent). Adding prior dose reduces treatment time to 2 
hours 33 minutes, and full AMPC is the fastest, taking only 1 hour 45 minutes; a 54% 
reduction compared to +TB only. The full AMPC case was also the safest case, 
yielding a maximum protected voxel dose of 27 CEM43 compared to 40 and 57 CEM43 
for the +prior dose and +thermal buildup cases, respectively.
2.3.1.3 Safety constraint thresholds
The previous results have shown that activation of the AMPC’s safety 
constraints reduces the thermal dose delivered to the protected voxels. Thus, to 
investigate the tradeoffs of different safety thresholds, multiple Toff /T on 
combinations were simulated.
Starting with the safety constraint thresholds used previously, Toff = 43.0 °C 
and Ton = 41.5 °C, Figure 2.7 shows the change in treatment time and maximum 
protected voxel dose when Toff is decreased in 0.5 °C intervals to 42.0 °C (the 
temperature below which thermal dose is assumed to no longer accumulate). Then, 
Toff is held constant at 42.0 °C (limiting the protected voxel dose to zero) while Ton
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Figure 2.7: Effect of safety threshold on treatment time and maximum PV thermal 
dose for the single pass-hottest neighbor treatment plan at 15 W with AMPC. Shaded 
region: Toff reduced in 0.5 °C increments, fixed Ton = 41.5°C. Unshaded region: Ton 
reduced in 0.5 °C increments, fixed Toff = 42 °C. Placing more stringent constraints 
on Toff reduces dose delivered to protected voxels at the expense of increased 
treatment time. Reducing Ton increases cooling time before the US is re-enabled, but 
also increases the available heating time before the next constraint violation occurs.
is decreased in 0.5 °C intervals, effectively varying the cooling duration per constraint 
violation. The results show that, if desired, the controller can be configured with a 
strict Toff value that disallows any significant thermal dose being delivered to the 
protected tissue; for example, when Toff /  Ton = 42.0/41.5 °C, protected voxel 
thermal dose was constrained to 0 CEM43, whereas a maximum of 27 CEM43 was 
delivered to the protected voxels when Toff /  Ton = 43.0/ 41.5 °C. Such increased 
safety comes at the expense of considerably increased treatment time; e.g., the fastest 
treatment when zero protected tissue dose was allowed (Toff /  Ton = 42.0/40.5 °C) is 
1.8 times as long as when 27 CEM43 was allowed (with Toff /  Ton = 43.0/ 41.5 °C).
Interestingly, when fixing Toff = 42.0 °C (to minimize protected voxel dose), 
Figure 2.7 shows that decreasing Ton, to force longer cooling intervals, yields a net 
time savings until Ton = 39.5 °C. After this point, the additional heating time afforded
is countered by the additional cooling time required, and total treatment time begins 
increasing again.
2.3.1.4 Accuracy and uniformity of thermal dose delivered
To investigate how accurately and uniformly the controller delivered the target 
dose to all treatment voxels, the final thermal dose distributions achieved for each 
controller optimization level were analyzed for the practical AMPC case of Figure 2.6: 
the single pass-hottest neighbor treatment plan with safety constraints enabled. The 
top row of Figure 2.8 shows a frequency distribution of dose for all treatment voxels 
in the tumor, while the bottom row shows the distribution of the doses for only the 
lowest dosed treatment voxel in each cell. Treatment time is dominated by the voxel 
that receives the lowest SAR in the cell, and thus overdosing in the other treatment 
voxels of the cell is expected. The target dose for all voxels was 240 CEM43, and the 
median doses delivered to the least dosed voxel of each cell were 1676, 886 , and 450 
CEM43 for the +temperature buildup, +prior dose, and +AMPC optimizations, 
respectively. The safety constraint threshold was exceeded 70, 44 and 30 times for the 
+temperature buildup, +prior dose, and +AMPC cases, respectively. Enabling each 
additional controller optimization level thus makes a significant improvement in 
treatment quality (more accurate dose delivery and fewer safety triggered cool-down 
periods). The full featured AMPC delivers the target thermal dose to the treatment 
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Figure 2.8: Histogram of final dose delivered as controller features are enabled. +Temperature buildup (+TB): (a) all treatment 
voxels, (b) minimum dose delivered to cells. +Prior dose (+PD): (c) all treatment voxels, (d) minimum dose delivered to cells. 
+AMPC: (e) all treatment voxels, (f) minimum dose delivered to cells.
2.3.1.5 Applied power and treatment time
When increasing the applied power magnitude there is a tradeoff between the 
increased rate of heating of the tumor vs that of the protected voxels. Figure 2.9 
demonstrates this tradeoff for the single pass-hottest neighbor treatment plan with full 
AMPC optimization and safety constraints enabled. Treatment time and dose to the 
protected voxels monotonically decreases with higher powers, but there is a “knee” in 
the curve beyond which the benefits of higher power rapidly decreases.
2.3.1.6 Effect of MR sampling time
MR acquisition time is valuable currency which can be spent, for example, to 
increase the imaging field-of-view, improve spatial resolution, and decrease noise, but
67
20
Power [ W ]
Figure 2.9: Treatment time and maximum protected voxel (PV) thermal dose as a 
function of applied ultrasound power for single pass-hottest neighbor treatment plan 
run with AMPC and safety constraints enabled. Values in parenthesis indicate the 
number of safety violations for each case.
these gains would be accrued at the expense of a longer interval between 
measurements. It would be beneficial if model prediction could help mitigate the costs 
of increasing the MR sampling interval and allow the clinician more freedom in 
selecting the imaging parameters. Simulations using the +AMPC and +prior dose 
optimization levels were run at a fixed power of15 W for 1, 3, 5, and 7 s MR sampling 
intervals to explore the effect of MR sampling time on treatment time and dose 
delivered to the protected voxels. As shown in Figure 2.10, the AMPC treatment time 
increased by 42% when the sampling interval increased from 1 s to 7 s, while the 
protected tissues' maximum dose increased by 28% over the same range; however, the 
AMPC outperforms the +Prior Dose optimization level by 19-31% over all sampling 
intervals, thus illustrating how AMPC can reduce treatment times even with long MR 
sampling times. For the AMPC, as the sampling interval increases, the temperature 
overshoot above the TOFF safety threshold also increases, but was < 0.2 °C for all cases.
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Figure 2.10: Treatment time (a) and maximum protected voxel thermal dose (b), as a 
function of MRTI acquisition interval; simulations run at 15 W with +AMPC or 
+Prior Dose optimization with safety constraints enabled using the single pass-hottest 
neighbor treatment plan. Implementing AMPC decreases both the treatment time and 
maximum thermal dose in the protected voxels for any given MR acquisition interval.
Similarly, the number of violations changed from 29 to 37 for the 1 s and 7 s MR 
sampling intervals, respectively.
2.3.2 In Vivo Results
2.3.2.1 AMPC repeatability
Figure 2.11 illustrates the final thermal dose deposited after each in vivo 
controller test for the treatment plan shown in Figure 2.4c. All four runs successfully 
delivered the target dose to all of the TVs, and the controller was able to create sharp 
boundaries between the target volume and surrounding tissues, with doses falling 
below 10 CEM43 after a distance of < 4 mm outside of the prescribed treatment volume. 
The first trial (Figure 2.11a) shows signs of secondary dose delivered due to proximity 
of the rabbit’s thigh bone to the treatment volume (see Figure 2.4b).
Of the 36 treatment cells treated in the four trials (nine cells per trial), the 
controller’s ability to monitor the temperature and thermal dose history of the entire 
volume allowed for one cell to be skipped entirely because the AMPC detected that it 
had already received the target dose during treatment of the previous cells. In two cells 
the controller deferred to the MRTI measurements and advanced the treatment to the 
next cell because the target dose had been delivered before a heating model could be 
identified dynamically. Most interestingly, the controller’s prediction that the 
switching dose for the active cell would be delivered between MRTI measurements 



























Figure 2.11: Final thermal dose maps in coronal slice of the treatment plane (perpendicular to ultrasound beam). Black 
squares indicate 1 x 1 x 1.5 mm treatment voxels. All treatment voxels were successfully treated, and minimal dose was 
deposited outside the prescribed treatment volume.
2.3.2.2 Temperature prediction accuracy during heating
The simplicity of the exponential heating model used by the AMPC for 
prediction is a benefit for ease of use because it can be identified and adapted during 
treatment. However, to evaluate the accuracy of the predictions, the temperatures 
predicted by the model at tj for the following measurement at t i+1 were compared to 
the temperatures actually measured at t i+1 for one in vivo rabbit trial. Each dot of 
Figure 2.12 represents a measured temperature and the corresponding error in the 
predicted temperature. The MRTI measurements were assumed to have zero-mean 
Gaussian noise and calculated to have a standard deviation of a = 1.2 °C by sampling 
an unheated 10 x 10 mm region of the rabbit thigh during the initial baseline 
temperature measurements. The results indicate that the heating model predicted the 
measured temperature within the measurement error, and the average prediction error 
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Figure 2.12: Prediction error as a function of measured temperature for all predictions 
made during a single treatment. MR measurements have o = ± 1.2 °C, calculated from 
an unheated tissue region.
2.3.2.3 Safety constraints
An in vivo evaluation of the safety constraints consisted of configuring the 
AMPC to monitor a plane of PVs 2 cm below the treatment volume with safety 
thresholds that allowed high normal tissue temperatures for short intervals (TOFF = 
45°C and Ton = 41°C). All treatment cells successfully received their 240 CEM43 target 
dose, and as shown in Figure 2.13, the controller constrained the temperature of the 
protected voxels by entering the cooling mode when TOFF was violated and then 
resuming treatment after all protected voxel temperatures were < Ton. This example 
included an additional, optional, controller feature that can be enabled to increase 
safety; this feature forces the PVs to cool to Ton between the heating of each cell even 
if Toff has not been breached. While this feature slowed the in vivo test treatment (as 
did the choice of path—which was made to demonstrate the controllers features, not 
to deliver the fastest treatment), the AMPC constrained the maximum dose delivered 
to the protected voxels to 8.4 CEM43.
2.4 Discussion
our simulation and in vivo results show that a real-time model-predictive 
controller can be practically implemented for MRgFUS therapy, and can reduce 
treatment times, optimize any treatment path, and actively protect normal tissues. 
Each controller optimization feature (+thermal buildup, +prior dose, and +adaptive 
model-prediction) makes significant contributions to those improvements (Figure 2.6), 
and model-prediction reduces treatment time by approximately 55% compared to only 
accounting for thermal buildup. Furthermore, the reduced heating times made possible 
with model-prediction also result in reduced dose delivered to protected tissues.
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Figure 2.13: Protected voxels’ maximum temperature vs time during in vivo treatment with Toff = 45 °C and Ton = 41 °C. For 
this demonstration only, an additional safety feature forced the treatment of each cell to begin with protected voxel temperatures 
< Ton- Maximum dose delivered to PVs was 8.4 CEM43.
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The nonlinearity of the thermal dose equation (Eqn. 2.1) makes accurate 
delivery of thermal dose difficult without model-predictive control (Figure 2.8). 
Modeling improves the accuracy of the delivered target dose by anticipating the 
nonlinear thermal dose effects, and has the additional advantage of reducing heating 
times by anticipating dose delivered during cool-down periods. The simple heating 
model used for prediction is sufficiently accurate (Figure 2.12), has the advantage of 
not needing a priori knowledge of tissue properties, and is amenable to on-line 
adaptation making the controller robust to tissue property changes during treatment. 
During in vivo evaluations, the AMPC always delivered the prescribed 240 CEM43 
target dose to the treatment voxels (Figure 2.11) and the boundary between treated 
and untreated regions was sharply demarcated with <10 CEM43 delivered to regions > 
4mm away from the target volume.
While the AMPC will automatically benefit from the work of others who 
accelerate MR temperature measurements [34], model-prediction will always be useful 
in decreasing treatment time because it anticipates the future dose to be delivered after 
the focal zone leaves a given treatment cell. Furthermore, model-prediction provides 
the flexibility to trade MR sampling time for increased coverage or higher resolution 
measurements. For example, Figure 2.10 demonstrates that performing the single 
pass-hottest neighbor treatment plan with model-prediction and an MR sampling time 
of 5 s would achieve the same degree of safety and complete the treatment faster than 
if treatment were performed with a 1 s MR sampling time but without model- 
prediction.
Our results reinforce the previously shown [29], [30] importance of considering
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the safety of healthy tissue when discussing treatment time, as unconstrained 
treatments can deliver >>240 CEM43 to normal tissues (Figures 2.5 and 2.6). In vivo 
evaluations of the configurable safety constraint showed that the AMPC reliably and 
automatically triggered cooling periods and limited protected voxel dose to < 9 CEM43 
without affecting treatment efficacy. While enabling the AMPC’s safety feature comes 
at the expense of longer treatment times, and relies upon capturing a large field-of-view 
(preferably with a fully 3D acquisition scheme), it is necessary for the safe treatment 
of clinically relevant tumors. Simulations showed the AMPC is capable of 
constraining dose to zero in tissues near the tumor (Figure 2.7), but the resulting 
treatment time may be difficult for the patient to endure. As Figure 2.7 illustrates, a 
more balanced selection of temperature constraints (T off/T on = 43.0/41.5 °C) reduced 
thermal dose in the intervening tissues to manageable levels (< 30 CEM43) while 
achieving a more reasonable treatment time.
We have also demonstrated that the AMPC can be used with arbitrary 
treatment paths defined by the user (Figure 2.5 and 2.11), which allows the treatment 
to be conformed to the tumor geometry and patient anatomy. Those results 
demonstrate that a single-pass treatment plan with small cells, each heated by a single 
focal zone location, is clinically practical and that path selection is important for 
minimizing both treatment time and dose delivered to protected tissues. ou r results 
indicate that a treatment plan that achieves a high degree of adjacency (proceeding 
from the completed cell to a nearby cell) takes maximum advantage of the temperature 
buildup in the tumor. This explains why the single pass-hottest neighbor treatment 
plan is 24% faster and delivers 23% less thermal dose to the protected voxels than the
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single pass-square spiral plan. Path selection becomes critically important once safety 
constraints are enabled since every safety-triggered cool-down period causes thermal 
buildup in the tumor to dissipate. Therefore, a path with a high degree of adjacency 
will more fully leverage the benefit of thermal buildup and maximize the volume 
treated per constraint violation. While several treatment paths have been 
demonstrated, further studies into optimal path selection are needed.
Our results with a real-time controller agree with previous optimization 
findings [46], [47] that: (1) the use of higher powers monotonically decreases treatment 
times, although a point of diminishing returns is reached after which minimal time 
gains are attained even with large increases in applied power (Figure 2.9); and (2) that 
an optimal interpulse cooling time exists (Figure 2.7), though it likely depends on 
many treatment parameters and this controller does not solve for the optimal cooling 
period.
Given our experience with this initial version of the controller, several 
improvements are planned to allow the adaptive model-predictive controller to further 
reduce treatment times and improve safety and efficacy. First, given the influential role 
of safety constraints in prolonging treatment time, a model of the heating and cooling 
of the protected voxels will be added to complement that of the treatment voxels (Eqn. 
2.2). While moving the focal zone along the scan path, the controller could then 
predict if the next heating pulse would involve a safety violation. Using both the PV 
and TV models, the violation could be avoided by replacing the fixed TON safety 
threshold with a real-time optimization that solved for the optimal starting temperature 
(Ton_opt) [46]. Once the PVs cooled to Ton_opt, the next heating pulse could begin and
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would complete without interruption. It may also be possible to speed up treatments 
by implementing a “fuzzy logic” constraint that would allow a few short-lived 
violations of Toff. This would eliminate the lengthy process of reheating a cell, after it 
had cooled, to deliver only a small amount of dose. Such a change would essentially 
be a combined temperature and dose safety system, with model-prediction expanded 
to include PV dose prediction.
Second, improved controller features, such as better treatment voxel models, 
could further reduce treatment times. In particular, (1) the current model assumes that 
a single exponential cooling period follows each heating pulse, a conservative 
approach that does not account for the complex temperature profiles that occur due to 
SAR overlap while treating future cells. Extension of the current TV cooling model to 
include more specific future events, something that is imminently feasible when the 
scan path is known, could reduce heating times. (2) If the heating rate is high enough 
so that a heating model cannot be identified before a cell is fully treated (see the 
Materials and Methods section), the AMPC cannot take full advantage of its predictive 
abilities and will likely over-heat the treatment cell. A better heating model approach 
is needed for these faster heating rates. For example, data-mining of large collections 
of treatment data combined with machine learning algorithms could yield better initial 
guesses for model parameters and improve model adaptation by applying information 
from similar tumor locations from other treatments, or more simply, from previous 
cells of the current treatment. (3) As a conservative approach, the current 
implementation places a high emphasis on MRTI measurements over model-predicted 
temperatures. In particular, the controller is allowed to switch treatment cells only
77
once within an MRTI interval to ensure at least one temperature measurement is 
acquired while treating each cell. In some cases this can introduce unnecessarily long 
heating times. Implementing the above changes would have the additional advantage 
of reducing the AMPC’s treatment time dependence on the MRTI sampling interval 
(Figure 2.10), allowing for improved MRTI imaging.
Other investigators have reported ablation rates of ~3-4 cm3/minute using 
multipass (volumetric) treatment strategies [12], [23], [24], values much larger than 
those attained in this study. The aforementioned studies obtained higher ablation rates 
because they performed treatments under different conditions. First, they did not 
predefine a target volume for ablation (as was done in this study), but instead executed 
a multipass treatment plan of fixed radius and evaluated the volume ablated post­
treatment. Second, the multipass treatment plan implemented in those studies was 
executed with much higher applied power (~130 W vs 15 W in most of the current 
study). Third, they treated large tumors. Lastly, and perhaps most notably, those 
studies did not implement safety constraints of any kind.
When the AMPC’S treatment conditions are made more equal to those used in 
prior studies, simulations show the AMPC can reach comparable ablation rates. For 
example, when the AMPC system is used with the treatment plan shown in Figure 
2.3a, a power of 130 W, a fast MRTI sampling interval, no safety constraints, and 
considering all ablated tissue, the AMPC’S resulting ablation rate was 4.9 cm3/minute 
(65 s treatment time). once the safety constraints are re-enabled (keeping the power at 
130 W), treatment time increases to 44 minutes and the ablation rate decreases to 0.04 
cm3/minute. This illustrates again how protecting a critical area in close proximity to
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the treatment volume can substantially prolong treatments.
In the future, an automatic mechanism for dynamically adjusting the 
transducer phases to ensure that the active cell receives the maximum SAR would 
further simplify treatments for the clinician. Finally, the AMPC presented here has 
been tailored to ablative FUS applications, but the concept of adaptive model- 
predictive control could benefit mild hyperthermia treatments. Instead of using model- 
prediction to anticipate nonlinear thermal dose effects, it could make it possible to 
approach the target temperature more quickly or with less overshoot. Additionally, 
real-time model adaptation could help compensate for tissue environment changes, 
such as blood flow, as well as make treatments more automatic by reducing the need 
for pretreatment controller tuning. Moreover, the slower rates of temperature change 
and longer heating durations encountered in hyperthermia treatments make it easier 
to dynamically derive and adapt a model (reduced need for fast MRTI). Lastly, model- 
prediction may also benefit hyperthermia treatments by allowing for increased MRTI 
field-of-view or improved resolution
2.5 Conclusion
The simulations and in vivo results show that adaptive model-predictive control 
can automatically deliver safe, effective MRgFUS treatments, and that activation of 
each of its multiple features successively reduces treatment time; path planning; 3D 
temperature measurements; accounting for prior dose; and model prediction. Such 
model-predictive control is practical for single-pass heating approaches despite their 
associated short heating intervals and need for rapid controller actions. The safety 
features of the AMPC provide clinicians with a flexible tool to safeguard healthy tissue
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to any degree desired while automatically performing reliable and effective treatments 
in significantly reduced times. Finally, the controller’s features provide extensive 
flexibility to the clinician: it is independent of the specified focal zone path; the safety 
vs speed tradeoff is customizable; and the model’s parameters are identified and 
adapted during treatment.
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CHAPTER 3
THREE-DIMENSIONAL MR ACOUSTIC 
RADIATION FORCE IMAGING
3.1 Introduction
Magnetic resonance-guided focused ultrasound (MRgFUS) is a promising 
noninvasive technology with wide ranging applications for the treatment of cancer [1 ]-
[3], localized drug-delivery [4]-[6], neuromodulation applications [7], [8], and blood- 
brain barrier opening [9]—[11]. One critical aspect of successfully using MRgFUS for 
any application is accurate positioning of the ultrasound focal spot as well as ensuring 
high quality focusing when the beam propagates through an aberrating tissue 
environment. Aberrations caused, for example, by tissue inhomogeneity in the breast
[12], [13] or by tissue-bone [14] interfaces could cause inadvertent damage to 
nontargeted tissues.
One clinically implemented approach to minimizing the risk of inadvertent 
damage to nontargeted tissue is to perform low-power interrogation pulses while 
measuring the resulting temperature distribution via MR proton resonance frequency 
(PRF) shift thermometry. Since the location and magnitude of the temperature rise is 
not known in advance, and many interrogation pulses may be required during a single 
treatment, unintended tissue damage may occur. Furthermore, the standard PRF
thermometry method is ineffective in fat, which would be especially problematic for 
therapies in organs such as the breast. Previous work has shown that the tissue 
displacement caused by focused ultrasound can be measured using MR acoustic 
radiation force imaging (ARFI), and that this technique can be used to localize the 
focal spot in 2D [15]—[17]. Since these MR-ARFI techniques use short ultrasound 
bursts on the order of 1-20 ms with low duty cycles (1-10%), minimal tissue heating is 
induced, making 2D MR-ARFI a safe alternative to low power interrogation pulses. 
Additionally, MR-ARFI generates displacement maps via motion encoding gradients 
(MEG) that produce a phase difference proportional to the tissue’s displacement; as a 
result, MR-ARFI is not susceptible to the same issues as PRF thermometry and can 
measure displacement in any tissue type, including fat.
Several methods for performing MR-ARFI have been presented using both 
spin-echo and gradient echo sequences, and several MEG schemes have been used 
including: (1) repeated unipolar [16], [18]; (2) bipolar gradients [17], [19], [20] (often 
repeated on both sides of the refocusing RF pulse in spin-echo sequences); (3) 
alternating bipolar gradients [21]; and (4) tripolar gradients [22]. In addition to beam 
localization, variations of these encoding schemes have been used to apply MR-ARFI 
for phase aberration correction [22]-[25], and tissue property determination [16], [19], 
but has been done with 2D imaging only. While 2D imaging has proved to be fast, the 
low displacements being measured (on the order of micrometers) sometimes required 
many averages to improve SNR. When used for beam localization, there is the risk 
that the peak energy deposition does not occur in the imaging plane because the user 
must place the measurement plane before the location of the focus is known.
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Furthermore, significant energy may be deposited outside the 2D field-of-view (FoV), 
which will not be captured but may impact beam quality. Measuring the displacement 
field over a large FoV in 3D would simplify and improve the accuracy of beam 
localization as well as improve knowledge of how intervening tissues affect beam 
quality. For the purpose of phase aberration correction, it is also possible that the 
increased information content provided by a 3D displacement field would improve the 
resulting focus or reduce the number of scans required to perform the optimization 
process. Also, 3D acquisition schemes have inherent signal averaging which improves 
SNR compared to a single 2D acquisition.
This chapter presents a method for performing 3D MR-ARFI with special 
attention paid to reducing imaging time and maintaining safe levels of tissue heating 
(< 6 °C). Several unique features are presented including: (1) an unbalanced bipolar 
motion encoding gradient waveform that allows for lower echo-times and higher echo 
train lengths (ETL); (2) a configurable kz reduction factor (KZRF) that reduces the 
number of US pulses required by firing only during the acquisition of a central subset 
of the kz partitions; and (3) pulse repetition time (TR)-level interleaving of the US-ON 
and US-OFF images which can either reduce the effective duty cycle by half (reducing 
tissue heating) or reduce the total imaging time by half (keeping duty cycle constant). 
This work also presents a parametric study of the tradeoffs among sequence 
parameters that influence imaging time and tissue heating including duty cycle (DC), 
TR, ETL, and KZRF.
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3.2 Methods
3.2.1 Sequence Overview 
A 3D spin-echo segmented EPI pulse sequence was modified to include an 
unbalanced bipolar MEG and optional flyback readout (Figure 3.1a). The area of 
MEG lobe A1 and crusher gradient lobe A2 is specified by the user, and the area of 
the second MEG lobe is set to A1 + A2 to ensure that the 0th order gradient moment 
sums to zero. The second MEG lobe effectively combines the crusher gradient of a 
standard spin-echo sequence (required to suppress stimulated echoes between 
successive TRs due to imperfect refocusing pulses) and the required gradient moment 
for motion encoding. An optical trigger output from the MRI pulse sequence 
synchronizes the firing of an ultrasound burst with the second lobe of the MEG. This 
optical trigger is converted to an electrical pulse compatible with the ultrasound device 
with custom made electronics designed and manufactured by the first author. The 3D 
spin-echo unbalanced bipolar ARFI sequence presented here has two additional 
features that enhance safety. First, the KZRF reduces the number of ultrasound pulses 
delivered by firing only while acquiring a central subset of all kz partitions. Second, 
instead of sequentially acquiring all k-space lines for a volume with ultrasound ON 
followed by the acquisition of all k-space lines with ultrasound OFF, acquisition of an 
US-ON image can be interleaved with an US-OFF image at the TR level. Thus, the 
same line of k-space will be read twice in consecutive TRs: once with an ultrasound 
burst and once with no ultrasound. This reduces the ultrasound duty cycle by a factor 
of two while keeping total scan time constant, or conversely the imaging time can be 
halved while holding the duty cycle constant.
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Figure 3.1: Overview of the experiment configurations, (a) Pulse sequence diagram for unbalanced-bipolar spin-echo 
ARFI sequence, (b) Phantom experiment setup. Phased array transducer approximately 10 cm below gelatin phantom. 
Geometric focus penetrates approximately 3 cm into the phantom, (c) Ex vivo cadaver breast used with breast specific 
MRgHIFU system consisting of phased array transducer and integrated 11-chanel RF coil.
3.2.2 Comparison of 3D ARFI and 3D PRF Thermometry 
A study in a tissue-mimicking phantom was performed to evaluate the ability 
of 3D ARFI to predict the position of peak temperature rise, and also to compare the 
characteristics of the 3D displacement pattern measured by MR-ARFI to the 3D 
temperature pattern measured by standard PRF thermometry. A gelatin phantom was 
constructed in-house from powder (Vyse Gelatin Co., Schiller Park, IL, USA) and 
positioned approximately 10 cm (Figure 3.1b) above a 256-element phased-array 
transducer (Imasonic, Besan^on, France) operating at 1 MHz (focal distance of 13 cm, 
aperture diameter of 14.5 cm, full-width-at-half-maximum 2 x 2 x 8 mm, f-number = 
0.90). The transducer was driven by electronics and software by Image Guided 
Therapy (Pessac, France). A deionized and degassed water bath coupled the phantom 
to the transducer. The water bath was degassed using a custom built degassing system, 
and a Hanna Instruments HI-9146 (Woonsocket, Rhode Island, USA) dissolved 
oxygen meter confirmed that the dissolved oxygen content was reduced to < 1.0 ppm. 
A single loop radio-frequency (RF) receive-only coil was positioned around the 
phantom approximately 3 cm from the bottom of the phantom. The 3D ARFI maps 
were acquired with a Siemens 3T Tim Trio MRI scanner (Erlangen, Germany) over a 
192 x 108 x 48 mm volume at 1.2 x 1.2 x 2.0 mm resolution. The raw k-space data 
were Tukey filtered along kz (using Matlab’s (Mathworks Inc, Natick, MA) tukeywin 
function with R = 0.85) to suppress Gibbs ringing artifact, and then zero-fill- 
interpolated to 0.2 x 0.2 x 0.5 mm voxel spacing to mitigate partial volume effects. 
Complex phase subtraction between the US-ON and US-OFF images was performed 
to produce phase difference maps, which were converted to displacement using the
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following equation that assumes constant tissue displacement over the encoding 
interval:
A D  = ------------------------- (3 1 )
2x y f encGMEG(t)5t ( . )
where 7  is the gyromagnetic ratio of hydrogen in MHz/T, Gmeg is the trapezoidal 
motion encoding gradient amplitude in mT/m, and A0 is the phase difference 
measured.
Unless otherwise noted, the following scan parameters were used: TR = 200 
ms, echo time (TE) = 45 ms, ETL = 9, bandwidth = 744 Hz/px, flyback readout, flip 
angle = 90°, MEamp = 30 mT/m, MEGAi = 259 mT-m^-ms, MEGA2 = 25 mLm 4-ms, 
acquisition time = 56 s, US power = 55 W, USdur = 10 ms. Holding the ultrasound 
power constant, 3D ARFI maps were acquired while electronically steering the focal 
spot to four locations (USx, USy, USz): (0, 0, 0) mm, (6 , 0, 0) mm, (12, 0, 0) mm, and 
(0, 0, 8) mm. These displacement maps were acquired with KZRF = 0.64 (US on 
during 18 of 28 kz partitions). ARFI displacement maps were also acquired at 
geometric focus with the TR-interleaving feature enabled such that the effective duty 
cycle was reduced to 2.5% with KZRF remaining 0.64. For comparison, a fully 
sampled ARFI dataset was acquired with US on during all kz partitions (KZRF = 1.0) 
and with no filtering along kz.
A second set of experiments were performed to investigate whether 3D ARFI 
could predict the location of peak heating as measured by PRF thermometry. 
Temperature maps of continuous-wave heating (8.8 W applied for 27.72 s) were
acquired using a 3D segmented EPI PRF thermometry sequence with flyback readout. 
Temperature was measured over the same volume, at the same resolution, with 
equivalent kz filtering, and at the same four electronically steered focal spot locations 
as the 3D ARFI maps. All scan parameters were equal to the 3D ARFI scan 
parameters except: TR = 33 ms, TE = 15 ms, FA = 20°, and acquisition time = 9.24 s. 
The 3D ARFI and 3D temperature datasets were compared and the error between the 
position of peak ARFI displacement and location of peak temperature change was 
quantified.
3.2.3 Ex Vivo Cadaver Breast 
After tests in phantoms, an experiment in a cadaver breast was performed to 
evaluate the sequence’s effectiveness at measuring 3D displacement fields in a realistic 
inhomogeneous tissue environment. The breast was secured to a plastic plate and 
positioned on top a breast specific MRgFUS system [26] with integrated 11-channel 
RF coil and 940 kHz 256-channel phased array transducer (Imasonic, Besan^on, 
France). 3D ARFI maps were acquired in ME2 mode over a 256 x 196 x 36 mm 
volume at 2 x 2 x 3 mm resolution. Other sequence parameters include: TR = 250 ms, 
TE = 53 ms, ETL = 7, bandwidth = 751 Hz/px, flyback readout, flip angle = 90°, 
MEamp = 28 mT/m, MEGAi = 305 mT-m^-ms, MEGA2 = 25 mT-m4 -ms, acquisition 
time = 49 s, US power = 44 W, USdur = 10 ms.
3.2.4 Parametric Safety Study of 3D MR-ARFI 
Three-dimensional imaging requires more phase encoding steps than 2D 
imaging, and while the primary penalty of this is increased imaging time, for 3D MR-
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ARFI this also increases tissue heating due to the increased number of US pulses 
delivered. To safely perform MR-ARFI, the induced temperature rise should be 
limited to 6 °C, both to avoid the accumulation of thermal dose [27] and to satisfy 
FDA limits on Thermal Index [28]. To this end, an evaluation of the tradeoffs among 
sequence parameters affecting tissue heating was performed. This study considered the 
field-of-view and resolution used to acquire the experimental 3D ARFI maps in the 
previous section. Parameters studied that affect tissue heating included: ETL, KZRF, 
TR /  DC, and TR-Interleaving (see Sequence Overview). Echo-planar imaging helps 
achieve practical imaging times and reduces the number of US pulses required to attain 
a 3D MR-ARFI map. However, ETLs can increase ghosting artifacts and increase TE, 
both of which diminish image quality and SNR. Using this sequence’s kz reduction 
factor feature, the number of US pulses can be reduced without changing the ETL by 
setting KZRF < 1. This reduces the spatial resolution of the displacement maps along 
the kz direction (while maintaining full resolution of the anatomical images), however 
these high frequency components may not be necessary to resolve the ARFI peak since 
the broadest dimension of the beam is also along kz. The number of US pulses, N us, 
required for a given ETL and KZRF is given by:
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N  N
N us = - ^ - ^  x K Z R F  (3.2)
us EFL
where Ny and Nz are the number of 3D phase encoding steps required for a given field- 
of-view and resolution. For the fixed FoV and resolution studied, Ny = 90 and Nz = 28. 
The number of US pulses required for a single US-ON 3D MR-ARFI map was
computed using Eqn. (3.2) with ETL ranging from 1 to 15 and for three KZRFs: [1.00, 
0.64, 0.50].
To rule out impractically long sequence configurations (>60 s per 
measurement), the imaging time to acquire a single measurement of a 3D MR-ARFI 
sequence was computed using:
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tAcq = ~ k f i ^ TR  (3.3)
A set of heating experiments were performed in the gelatin phantom to quantify 
the temperature increase induced by the ultrasound pulses of varying duty cycles. 
During acquisition of the US-ON image, Eqn. (3.4) relates the TR interval, the US- 
pulse duration (USdur) and duty cycle (DC) when the TR-interleaving feature is 
disabled.
UQ
DC = x 100 (3.4)
TR
For these experiments, the ultrasound power and pulse duration were held 
constant (55 W and 10 ms, respectively) while TR was varied to adjust the duty cycle. 
The following TRs (duty cycles) were tested: 100 ms (10% DC), 200 ms (5% DC), 400 
ms (2.5% DC). Temperature rise was measured with a standard 3D PRF thermometry 
sequence with similar parameters to those described previously, but with a reduced 
FoV to improve the temporal resolution (4.16 s instead of 9.24 s). For each DC tested, 
the maximum temperature of each time frame was computed, and a double
exponential curve was fit to these temperature data via least-squared error 
minimization. These curves were used to evaluate how much heating occurred for a 
given number of US pulses at each duty cycle.
3.3 Results
3.3.1 Comparison of 3D MR-ARFI with 3D PRF Thermometry 
A representative 3D displacement pattern measured by the SE unbalanced- 
bipolar MR-ARFI sequence while firing at the geometric focus is shown in Figure 3.2. 
Slices through the displacement maps measured when electronically steering the US 
beam from (0, 0, 0) to (6 , 0, 0), (12, 0, 0) and (0, 0, 8) mm are shown in Figure 3.3a- 
d, with slices longitudinal to the beam through the point of maximum displacement. 
For comparison, the 3D PRF thermometry maps are shown in Figure 3.3e-h. The 
drop in maximum displacement and temperature rise as well as a measurement of the 
actual beam deflection as the US beam was steered electronically from geometric focus 
is illustrated in Figure 3.4. Maximum displacement fell from 32 ^m at geometric focus
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Figure 3.2: 3D ARFI volume measured at geometric focus. (a) Cut away view of 3D 
displacement map, (b) slice transverse to US beam through maximum displacement, 
(c-d) slices longitudinal to US beam through maximum displacement.
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Figure 3.3: Comparison of 3D ARFI and 3D temperature patterns while electronically 
steering to multiple positions. Slices are longitudinal to US beam propagation and cut 
through maximum displacement/temperature. While the 3D ARFI patterns are 
generally broader than the 3D temperature patterns, a clear peak exists and matches 
the location of the temperature peak within 0.4 mm in the transverse direction and 1.0 
mm in the longitudinal direction. The 3D ARFI maps captured the expected beam 
tilting and decreased displacement associated with electronic steering in addition to 
the near-field effects.
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Figure 3.4: Comparison of temperature and ARFI profiles when electronically steering 
the US beam. (a) Profiles along transverse line through maximum displacement (top) 
and maximum temperature (bottom) as beam is electronically steered to from (0 , 0 , 0) 
mm (black) to (6 , 0, 0) mm, (medium gray) and (12, 0, 0) mm (light gray). Numbers 
above lines indicate measured beam deflection. (b) Profiles along longitudinal line 
through maximum displacement (top) and temperature (bottom) as beam is steered 
from (0 ,0 ,0) mm (black) to (0 , 0 , 8) mm (light gray).
to 18 pm when the beam was steered to (6 , 0, 0) mm (a 44% reduction), and to 11 pm 
at (12, 0, 0) mm (a 65% reduction), despite the output power being held constant. The 
movement of the peak displacement tracked the prescribed beam deflection within 
0.4 mm when steering in the US-x direction (perpendicular to the US beam), and was 
within 1.5 mm when steering in the US-z direction (along the US beam). Evaluating 
the same quantities using the 3D temperature maps, at geometric focus the maximum 
temperature measured was 11.5 °C which was reduced to 10.0 °C when steering the 
beam to (6,0,0) mm (a 13% reduction), and to 7 °C at (12,0,0) mm (a 39 % reduction). 
The error between the location of peak temperature rise and the desired beam 
deflection distance was within 0.2 mm when steering in the US-x direction and within 
0.5 mm when steering in the US-z direction.
3.3.2 Ex vivo Cadaver Breast 
Slices through the 3D displacement volume measured in ex vivo cadaver breast 
are shown in Figure 3.5. Because of the high fat content of the breast, it was not 
possible to measure temperature using the PRF thermometry method, however, the 
fat content did not impact the ability to measure ARFI displacement.
3.3.3 Parametric Study of Heating due to 3D MR-ARFI 
Figure 3.6 summarizes the critical sequence parameters and their effects on 
tissue heating. Figure 3.6a illustrates the imaging time required for several TR and 
ETL combinations. For a given combination of ETL and TR, it is possible to look up 
the corresponding number of US pulses required in Figure 3.6b for various kz reduction 
factors. For example, with ETL = 9, TR = 200 ms, and KZRF = 1.0, Figure 3.6a 
shows that tAcq = 56 s while Figure 3.6b indicates 280 US pulses would be required. 
According to Figure 3.6c, which shows the tissue heating as a function of the number 
of US pulses for each duty cycle, acquiring a 3D ARFI map with this configuration 
would result in a 6.2 °C temperature rise which violates the 6 °C safety limit. However, 
by reducing KZRF to 0.64 (such that only 18 of the 28 kz partitions are acquired with 
US on), the number of US pulses decreases to 180 and induced tissue heating is 
reduced to 5.6 °C. The TR2-interleaving mode can either reduce the effective duty 
cycle by half (to 2.5%), which in this case would limit the induced temperature rise to
3.1 °C, or double imaging speed by reducing TR by 50% (duty cycle remains 5.0%). In 
this mode (TR = 100 ms, KZRF = 0.64, and ETL = 9), imaging time would be only 








Figure 3.5: 3D displacement maps in cadaver breast. (a) Slice transverse to US beam. 
(b) Slice longitudinal to US beam. (c) Magnitude image at approximate location 
shown in (b).
Echo Train Length Echo Train Length US pulse #
Figure 3.6: Effect of ARFI imaging parameters on resulting tissue heating, (a) Imaging time, calculated from Eqn. (3.3), as a 
function of ETL for TR = 400, 200, and 100 ms. (b) Number of ultrasound pulses delivered (Eqn. (3.2)) as a function of ETL 
and KZRF = 1.0 (Full sampling), 0.64, and 0.5. (c) Tissue heating as a function of number of US pulses for duty cycle = 10.0%, 
5.0%, and 2.5%. Curves are the result of double-exponential fits to experimentally measured tissue heating data with the 
ultrasound pulse duration kept constant at 10 ms. The dashed line indicates the 6 °C safety limit on induced tissue heating.
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The displacement profiles for the fully sampled mode (KZRF = 1.0, no filtering 
in kz), partial sampled mode (KZRF = 0.64, tukey filter in kz) and TR2 interleaved 
mode (KZRF = 0.64, tukey filter in kz) are shown in Figure 3.7. The location of peak 
displacement agree in US-x/y for all three modes, while the TR2 interleaved mode 
differs along the US-z direction by 0.5 mm. The magnitude of maximum displacement 
measured by the full and partial modes agree within approximately 10%, while the 
TR2 interleaved mode shows significantly less displacement, albeit a clear peak exists 
that is suitable for focal spot localization. Neither the reduction of KZRF from 1.0 to 
0.64, nor the filtering performed along kz diminished the displacement profile's quality 
appreciably.
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Figure 3.7: Comparison of displacement profiles measured by different acquisition 
schemes. (a) Displacement profiles along the US-x direction, (b) displacement profiles 
along the US-z direction. [Full] has US on during all kz partitions (KZRF = 1.0) and 
no k-space filtering, [partial] has US on during 18/28 kz partitions (KZRF = 0.64) and 
filtering along kz, and [TR2] has TR interleave mode enabled with KZRF = 0.64 and 
kz filtering. In all schemes the locations of the peaks agree within 0.5 mm, but partial 
and TR2 reduce the induced temperature rise to 5.6 °C and 3.0 °C, respectively, from
6.2 C in the full case.
3.4 Discussion
The choice of motion encoding gradient (MEG) proved to be beneficial in 
reducing imaging time and tissue heating. Other common motion encoding strategies 
employ two bipolar gradients pulses on either side of the 180° pulse (for SE sequences), 
single bipolar pulses with alternating polarity (for GRE sequences), or tripolar pulses. 
The double bipolar approach increases the TE or limits the ETL that can be used, 
which increases imaging time in a 3D acquisition and increases tissue heating due to 
repeated application of US bursts. A single bipolar approach helps reduce TE, but if 
alternating polarity gradient encoding is used, such that there is no US-OFF image, 
then the number of US pulses is doubled which would increase tissue heating. Tripolar 
gradients have the benefit of producing more self-canceling eddy currents, but increase 
the risk that the tissue is still displaced during the 3rd gradient moment thus incorrectly 
subtracting motion encoding phase. The unbalanced bipolar MEG gains time 
efficiency by combining the motion encoding and crusher gradient moments allowing 
the US to be on for a maximum amount of time. Since there is only one MEG (before 
the 180° pulse), motion encoding does not compete for time with the EPI readout after 
the 180° pulse, allowing for shorter TEs and larger ETLs.
The results in Figure 3.3 and Figure 3.4 demonstrate that 3D ARFI maps can 
localize the focal spot in all three dimensions in a single scan and that peak 
displacement is a good predictor of the location of peak temperature rise. This could 
be important in applications such as FUS treatments of breast where PRF temperature 
imaging may not be able to measure the temperature due to fat content of the tissue, 
or in brain treatments where performing a test heating to localize the focal spot may
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cause unwanted tissue heating. The errors between the location of peak temperature 
and displacement were within one measure voxel (before zero-filling). After zero- 
filling, the maximum difference in location of peak displacement vs temperature was 
0.4 mm transverse to the US beam and 1.0 mm along the US beam. While it does not 
improve the fundamental resolution of the image, zero-filling helps reduce errors 
introduced by partial volume effects and thus can improve the localization of the focal 
spot, especially in the case of ARFI where the profile has a sharp peak along the beam’s 
transverse direction. Since the PRF thermometry sequence is based on a GRE pulse 
sequence while the unbalanced-bipolar ARFI sequence is based on a SE sequence, the 
temperature imaging is susceptible to additional distortion (caused by, for example, 
static field inhomogeneities), which may not affect the SE ARFI sequences. The ARFI 
sequence also benefits from a longer TR and higher flip angle which may increase the 
available signal. However, these benefits are offset by the ARFI sequence’s relatively 
long TE (45 ms vs 15 ms) and the additional vibration and eddy currents caused by the 
strong motion encoding gradients.
The cadaver breast sample was highly inhomogeneous and contained a 
significant amount of fat which made it impossible to measure temperature with the 
PRF method. However, 3D displacement fields were successfully measured (Figure 
3.5), and the 21.3 |im peak displacement measured is similar in magnitude to the tissue 
mimicking phantom tests. This demonstrates the usefulness of 3D ARFI to fully 
localize the focal position regardless of tissue type, and in a scenario where standard 
test heating approaches would be unsuccessful.
At the power tested, the induced temperature rise for a 2.5% duty cycle reached
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steady state of 3.5 °C, and thus imaging for long durations could be performed safely 
without violating the 6.0 °C safety threshold (Figure 3.6). However, at the 5.0% and 
10% duty cycles it becomes important to consider the number of US shots delivered, 
as the 6 °C threshold is violated after 236 and 80 shots, respectively. Using Figure 3.6 
to guide the selection of imaging parameters for the imaging volume tested, ETLs of < 
5 are impractical either because the imaging time is too long (> 60 s) or because the 
number of US shots required results in significant tissue heating. On the other hand, 
as the ETL is increased there are diminishing returns in regard to imaging time and 
tissue heating. Higher ETLs can also increase ghosting artifacts as well as TE, which 
degrades SNR, and so ETLs in the range of 7-11 strike a balance between image 
quality, imaging time, and safety.
Adjusting the KZRF from 1.0 to 0.64 mitigated tissue heating concerns by 
reducing the induced temperature rise from 6.2 °C to 5.6 °C. While this also reduces 
the effective resolution of the 3D ARFI maps along the US-z direction, generally 
focused ultrasound transducers have an ellipsoid shaped focal zone with one 
dimension being elongated and this reduces the spatial resolution requirements along 
that dimension. The datasets shown in Figure 3.2-Figure 3.5 were acquired with 
KZRF = 0.64, but in Figure 3.7 it can be seen that the displacement profile shape and 
location of peak displacement did not differ appreciably when full sampling was used 
(KZRF = 1.0) and filtering was disabled. This indicates that the high frequency 
components did not contribute significantly to the localization of the focal spot and 
thus acquiring them with US on superfluously heats the tissue. Furthermore, the 
higher kz spatial frequencies were acquired (albeit without US), so the magnitude
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images needed for correlation of the MR-ARFI maps with patient anatomy would 
retain their full prescribed resolution.
Further reductions in tissue heating were achieved by enabling the TR- 
interleaving feature, which was used to halve the effective duty cycle. For comparison, 
sequential acquisition of the US-ON and US-OFF images using an US-pulse duration 
of 10ms, a TR of 200ms (5% DC), and KZRF = 1.0 resulted in a 6.2 °C temperature 
rise. By activating TR-interleaving and setting KZRF = 0.64, the TR remained 200 ms 
but the effective DC was reduced to 2.5% because the US fires every other TR. 
Consequently, the maximum tissue heating was lowered by 50% to only 3.1 °C. 
Alternatively, the TR-interleaving mode could have maintained the 5.0% DC and 
halved total imaging time by reducing the TR to 100 ms without causing unsafe tissue 
heating. Without TR interleaving, a TR of 100 ms (10% DC) would cause unsafe 
heating for any choice of ETL or KZRF studied since the safety threshold is violated 
after 80 US shots and even an ETL of 15 with KZRF = 0.5 requires 84 shots. However, 
by interleaving the acquisition of the US-ON and US-OFF images every TR, the 
imaging speed of TR = 100 ms is available with the tissue safety of the TR = 200 ms 
case.
The location of peak displacement measured by each imaging mode (full 
sampling, partial sampling, and TR-interleaved) agreed except for the US-z location 
in the TR2 mode which differed by 0.5 mm. More significantly, however, was that the 
TR2 mode measured a lower peak displacement of 7.4 |im vs 28.6 um for the fully 
sampled case. To investigate this result, an additional test was performed where three 
measurements were acquired in [OFF]-[ON]-[OFF] order, but where only the first two
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were interleaved and the third was acquired without interleaving. The phase of each 
measurement before subtraction, shown in Figure 3.8a, reveals that the first 
measurement has a phase profile akin to that of the second, US-ON, measurement 
despite it lacking US pulses. This is not seen in the third measurement, which also 
lacked US pulses but whose acquisition was not interleaved with an US-ON 
measurement. This indicates that signal pathways exist which allow stimulated echoes 
to contaminate the phase of the first US-OFF measurement, and thus reduce the 
measured displacement. When the third, US-OFF and un-interleaved, measurement 
is used as the reference phase, the measured displacement increases to 19.1 ^m which
106
Figure 3.8: Fully sampled mode compared to TR-interleaved mode. (a) Phase for three 
TR2 measurements before subtraction. The first (OFF) and second (ON) 
measurements were interleaved while all k-space lines for the third (OFF) 
measurement were acquired sequentially without interleaving. Though #1 and #3 
both lack US pulses, a phase bump exists in #1 that mimics that of #2 (which had US 
pulses). This indicates that stimulated echoes are distorting the phase measurement of 
#1, which artificially reduces the displacement measured by TR2 mode (Figure 3.7). 
(b) Displacement measured by ME2 mode computed to TR2 mode when #1 vs #3 is 
used as the reference phase. Eliminating the phase offset seen in #1 by using #3 as the 
reference phase increases the measured displacement.
agrees more closely to the displacement measured by ME2 mode (Figure 3.8b). 
Stimulated echoes may play a role in exaggerating the phase induced during ME2 
mode which could account for the remaining difference between ME2 and TR2. 
Future investigations and sequence improvements could disrupt the offending signal 
pathways and improve signal fidelity in both modes.
As a final note on safety, these measurements represent a worst-case scenario 
as the phantom is not perfused, and the US power used in both the phantom and breast 
studies generated tissue displacements that were larger than required for focal spot 
localization. Safety concerns under in vivo conditions should be allayed both by tissue 
perfusion, which accelerates tissue cooling, and reduced power. Using the study of 
sequence parameters and features to guide the selection of imaging parameters, 3D 
MR-ARFI maps can be safely acquired in a time efficient manner over a large field-of- 
view.
As with all 3D acquisition schemes, this sequence is sensitive to motion, both 
of the imaging subject, and peripheral objects (such as the coupling water bath) that 
may generate susceptibility changes in the imaging volume. It may be possible to 
reduce these side effects by adding a phase navigator to perform correction during 
image reconstruction. Nevertheless, this 3D ARFI technique could be beneficial for 
applications such as breast imaging and brain imaging where there is little organ 
motion, or the motion can be constrained.
In the future, it may be possible to further reduce the tissue heating and 
acquisition by integrating existing k-space undersampling techniques [29], [30] into 
this 3D ARFI sequence. Additional investigation into the use of 3D MR-ARFI for the
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purpose of phase aberration correction would also be beneficial, as the 3D 
displacement field provides significantly more information with which to perform 
correction.
3.5 Conclusion
A 3D spin-echo pulse sequence employing a novel unbalanced bipolar motion 
encoding gradient was presented and successfully tested in phantoms and ex vivo 
breast tissue. This sequence can safely measure displacement due to acoustic radiation 
force over a large FoV and at high resolution in reasonable scan times (< 60 s per scan). 
Comparisons to 3D PRF temperature imaging showed that the 3D ARFI sequence 
accurately localized the ultrasound focal spot using a single scan. The ability to cover 
a large FoV increases the likelihood that the peak displacement is captured, and that 
any near-field effects, such as reflections of bone interfaces, are observed before 
potentially harmful heating is attempted. The ability of 3D ARFI to localize the focal 
spot, even in a cadaver breast containing fat, proved that 3D ARFI is a useful 
alternative to standard low-power heating methods, which failed in this scenario. The 
tradeoffs among imaging parameters and tissue heating were explored in a parametric 
study of TR, ETL, and duty cycle. It was found that ETLs in the range of 7-11 strike 
a good balance between improving imaging time, reducing tissue heating, and 
managing image artifacts. Advanced sequence features such as kz reduction factor, 
where the US is enabled only during a subset of all kz partitions, and TR-interleaving, 
where the acquisition of US-ON and US-OFF images alternate every TR, were tested 
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CHAPTER 4
SIMULTANEOUS ACQUISITION OF 3D ACOUSTIC 
RADIATION FORCE IMAGING AND PRF 
THERMOMETRY USING A MULTI­
CONTRAST APPROACH
4.1 Introduction
In Chapter 3, a method for performing 3D acoustic radiation force imaging 
(ARFI) was presented using a spin-echo sequence. While it was found that 3D ARFI 
could be done safely, standalone PRF thermometry imaging was required to measure 
the induced temperature rise; this would be time consuming and potentially hazardous 
to perform after every 3D ARFI measurement. Consequently, it would be beneficial if 
the temperature rise induced by 3D ARFI could be monitored without additional 
imaging scans. This chapter presents a second 3D ARFI technique that is capable of 
simultaneously measuring tissue displacement and tissue heating.
The spin-echo method presented in the previous chapter is not sensitive to 
temperature change resulting from the proton resonance frequency shift (PRF), and so 
this ARFI method uses a gradient-recalled echo (GRE) pulse sequence that preserves 
the sensitivity to temperature change. However, once motion encoding gradients are 
added to the sequence, the measured phase has contributions from both tissue
displacement and tissue heating, and so a means of attributing the contribution made 
to the total phase change from each source is required. Other investigators have 
achieved this in 2D by alternating the polarity of the motion encoding gradients [1]; 
however, this approach has the downside of increased artifacts due to noncanceling 
eddy-currents and increased noise in the images [2]. This chapter presents a novel 
method of acquiring simultaneous temperature and displacement measurements using 
a multicontrast acquisition, without alternating the gradient polarity, and is also the 
first to do so in 3D. While multicontrast acquisitions have been used to measure other 
quantities, such as temperature, T1, and T2*, [3]-[6], this is the first use of a 
multicontrast acquisition for performing displacement measurements.
This new 3D ARFI method samples the same lines of k-space multiple times 
within a single TR interval, and it will be shown that this extra information can be 
used to solve for the constituent parts of the total phase change. This approach is 
particularly well suited to MR-ARFI because long TRs are usually required to prevent 
overheating the tissue. Thus, in most ARFI schemes, data acquisition consumes only 
a small fraction of the TR interval and the remaining time is wasted. This method 
makes more efficient use of the TR interval by filling the dead time with repeated 
measurements of the same k-space lines. This has two positive outcomes: (1) the 
signal-to-noise ratio (SNR) of the image is improved through signal averaging, and (2) 




The sequence timing diagram used throughout this chapter is shown in Figure 
4.1. The sequence is based on a GRE segmented echo planar imaging sequence that 
was modified to include a bipolar motion encoding gradient (MEG) and to allow 
repeated acquisitions of the readout train. Each repetition of the readout is referred to 
as a “contrast” and the number of contrasts allowed is limited by the TR interval. The 
ultrasound burst was synchronized with the second lobe of the MEG by means of an 
optical trigger emitted by the sequence. The device described in Appendix A was used 




Figure 4.1: Experiment configuration summary. (a) GRE multicontrast ARFI pulse 
sequence diagram. Readout is repeated multiple times with an echo forming at TE-1, 
TE-2, etc. (b) Experiment set up with phased-array transducer positioned 13 cm below 
a gelatin phantom. Transducer focus penetrated 3 cm into the phantom.
4.2.1 Determination of the ARFI and Temperature Phase Contributions 
Reconstruction of the multicontrast data must be done differently than in the 
previous chapter which performed a simple complex subtraction between a reference 
image with no ultrasound and a second image with ultrasound. The first step is to 
generate a regular complex image for each contrast for both the ultrasound-off and 
ultrasound-on measurements. Let the i-th contrast of the measurements with 
ultrasound be denoted as ON^, and let denote the *-th contrast of the images
without ultrasound. An example of the phase for ON1 through ON3 is shown in Figure 
4.2a-c. Since each contrast is acquired at an increasingly later echo time, the signal 
decreases for each successive contrast. Furthermore, the signal decays at a rate of T2*, 
which is faster than the spin echo technique of Chapter 3, since this sequence is based 
on a gradient recalled echo instead of a spin-echo acquisition. The next step is to 
perform a complex phase subtraction between ONjt and OFF.\ for each contrast to 
attain a phase difference, A ^ , for each contrast. At this point, it is still unknown how
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Figure 4.2: Image reconstruction for multicontrast sequence. (a-c) Phase maps for 
three contrasts demonstrating reduction in signal over time. (d) Example of separating 
displacement and temperature phase contributions by weighted fit. Slope of the line 
gives phase from temperature while intercept gives phase from displacement.
much of A0, is due to temperature change vs displacement. To resolve this, it is first 
noted that the phase due to temperature accrues as:
A $ T = ~fB0A T - T E  (4.1)
while the phase due to displacement accrues as:
A0d = 7  f  MEG(t)AD(t)dt  (4.2)
0
and the total phase is then:
A0, = 2 n jB 0A T  - TE  +  j  f  MEG(t)AD(t)dt  (4.3)
0
Since A ^ D is not a function of TE, and it is reasonable to assume the tissue 
displacement is the same for every ultrasound shot, then A ^ D will be a constant in the 
previous expression. Furthermore, if A T  changes slowly over the period of a single 
TR, then the term 2n^B0A T  in Eqn (4.3) is also a constant, reducing Eqn (4.3) to:
A ^ i = m - TE  +  b (4.4)
This reveals that the total phase difference evolves as a linear function of the echo time 
of each contrast, and that the displacement phase is the total phase at TE = 0. 
Intuitively, this makes sense since in the absence of tissue heating there would be a 
constant phase associated with a given displacement, as was the case with the SE
117
118
technique in Chapter 3. Thus, the final task is to perform a linear least-squared error 
fit to the vs TE of each voxel, at which point temperature can be solved for with:
where the displacement has been reduced to a weighted time-average displacement 
over the encoding interval, and the integral in the denominator is the known motion 
encoding gradient area. Figure 4.2d demonstrates the linear fit for one voxel with 
corresponding conversion of slope/intercept to temperature/displacement, and where 
the additional step of weighting the fit by the signal magnitude has been taken to 
account for the decrease in SNR over time. While this process increases the 
reconstruction time compared to the simple subtraction reconstruction method of the 
spin-echo technique, each voxel is independent and the task is easily computed in 
parallel on a CPU or GPU. If reconstruction speed were still a constraint, 
reconstruction could be limited to a region of interest surrounding the focal spot.
4.2.2 Validation of Multicontrast Sequence 
Experiments in a gelatin phantom compared the displacement and temperature 
measurements derived from the multicontrast sequence to those of the spin-echo
m = j B ^ a A T  ^  A T  = —
j B 0a (4.5)
and displacement is given by:
(4.6)
ARFI and standard PRF thermometry sequences, respectively. The relevant sequence 
parameters for each sequence are summarized in Table 4.1. All ARFI measurements 
used a pulse duration of 10 ms and an applied power of 44 W. The standard PRF 
thermometry sequence used the same ultrasound power and duty cycle as the ARFI 
scans (44 W, 10 ms on, 190 ms off), but had a faster acquisition time so the 
measurement that came closest in time to ARFI dataset was used for comparison.
A second experiment was performed to address an unsolved question regarding 
how well the location of peak heating and peak displacement agree along the beam’s 
propagation direction. Previous experiments, which were not capable of simultaneous 
ARFI and temperature measurement, have indicated that peak displacement may 
occur more proximal to the transducer than peak temperature. However, this has been 
a difficult experiment to perform since it required using two different sequences with
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53 85 9 1 x 1 x 2.5 192 x 108 x 50 284
SE
ARFI 200 45 53 90 9 1 x 1 x 2.5 192 x 108 x 50 284
PRF 35 16 11 20 9 1 x 1 x 2.5 192 x 108 x 50 N/A
FA = Flip Angle. ETL = echo train length, i.e., the number of k-space lines acquired 
per contrast.
different acquisition schemes. Most notably, the standalone ARFI sequence was based 
on a spin-echo sequence while the thermometry sequence was a GRE based sequence. 
Since these two ways of forming an echo have different distortion and warping 
characteristics, it was difficult to register the two datasets precisely. With the 
multicontrast sequence, no registration is required because temperature and 
displacement are acquired simultaneously. For these tests, the volume was rotated 
such that phase encode direction with 1.0 mm resolution was along the ultrasound 
direction, instead of the slice encoding direction with 2.5 mm resolution. All datasets 
were zero-fill interpolated from their acquired resolution to 0.5 x 0.5 x 0.5 mm voxel 
spacing to reduce partial volume effects.
4.3 Results
A comparison of the 3D displacement maps measured by the multicontrast and the 
spin-echo techniques are shown in Figure 4.3, while Figure 4.4 shows the 3D 
temperature maps measured with the multicontrast sequence compared to the 
standard MR thermometry sequence. The peak displacements measured by each 
method agree to within 0.5 |im, while peak temperatures agree to within 0.8 °C. While 
both metrics agree within the noise of the measurements, it should be noted that due 
to the differing acquisition intervals, it was not possible to acquire a standard PRF 
temperature map with heating duration identical to that of the multicontrast 
temperature maps. As a result, the standard PRF sequence had a slightly longer 
heating duration. When the imaging direction with highest resolution was aligned with 
beam’s direction of propagation, the location of peak heating and peak displacement 












Figure 4.4: Comparison of 3D temperature maps as measured by the multicontrast 
approach and standard PRF thermometry. Note: duration of heating in the PRF 
method is slightly longer.
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Figure 4.5: Comparison of MC-ARFI and MC-Temperature when axis of best 
resolution (1 mm) was aligned with beam propagation direction. Location of peak 
ARFI and temperature agree to within 0.5 mm.
4.4 Discussion
The displacement maps in Figure 4.3 demonstrate qualitatively that the two 
measurement schemes produce similar 3D displacement fields. Additionally, the 
agreement of peak displacement to within 0.5 ^m indicates that the multicontrast 
approach can be relied upon as a means of ARFI measurement. The temperature maps 
in Figure 4.4 show signs of increased deviation between the two methods. However, 
the general shape of the patterns are similar, and the maximum temperatures agree 
within the noise of the measurements. This may be a sign that the weighting function 
used when performing the per-voxel linear fit to phase was not optimal, or there was 
simply too much signal decay by the later echoes which resulted in an improper slope 
calculation. Further investigation into the most appropriate and robust weighting is
warranted. In all cases, tissue heating was less than 4.5 °C which indicates this method 
is safe. The result in Figure 4.5 resolves an important question that has been difficult 
to definitively answer without simultaneous acquisition of temperature and 
displacement: does the location of peak ARFI displacement occur closer to the 
transducer than does the location of peak temperature? Figure 4.5 indicates that, at 
least in homogeneous media, the answer is: no, in fact they coincide quite closely. 
According to the new multicontrast measurement, peak ARFI displacement occurred 
within 0.5 mm of peak temperature, which is less than the size of a single voxel. This 
demonstrates a benefit of simultaneous measurements in addition to providing a safety 
monitoring mechanism.
Finally, for beam localization purposes, this sequence could be used without 
separating the effects of ARFI and temperature. Since both indicate the presence of 
the ultrasound beam, and there is now evidence that the two effects overlap even in 
the z direction; the combined sensitivity to temperature and displacement may improve 
the accuracy of focal spot determination. Of course the temperature and displacement 
effects could be separated at any time, but this “combined” phase could provide a 
useful third signal.
In future, this multicontrast technique could be applied to the determination of 
tissue mechanical properties and their temperature dependence. By continuously 
measuring ARFI and temperature, it may be possible to observe a mechanical change 
in the tissue experimentally, and have a record of the temperature history that 
generated that change. This may help provide another means of measuring tumor 




This chapter has presented and validated a new method of safely measuring 
acoustic radiation force and temperature simultaneously. By acquiring multiple 
acquisitions of the same k-space lines every TR, it was shown that the contributions of 
displacement and temperature to the total measured phase could be attributed to the 
proper source. This method’s measurements of temperature and displacement agreed 
favorably with those of independent techniques. The displacement peak matched to 
within 0.5 |im of a standard spin-echo ARFI method, and maximum temperature 
agreed to within 0.8 °C. This new tool was used to answer an important question: does 
peak temperature and peak displacement occur at a different location along the beam 
propagation direction? It was found that both peaks coincide within approximately 0.5 
mm, a result that is more reliable than when attempted with separate ARFI and 
temperature scans since this result is self-registered. When beam localization is the 
primary goal, this method may be used in a third mode where only the total phase 
difference is considered since the sensitivity to both temperature and displacement 
could provide a clearer indication of the beam’s center.
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CHAPTER 5
CONCLUSION
This dissertation has presented several methods for improving focused 
ultrasound thermal therapies. In Chapter 2, a new adaptive model-predictive controller 
was successfully demonstrated in vivo, and simulations showed that its predictive 
features helped reduce treatment time by approximately 50% compared to treatments 
performed without prediction. The predictive features also helped mitigate the 
negative effects of longer MR sampling intervals, allowing more flexibility in selecting 
imaging parameters. Chapter 3 presented a new technique for performing MR-ARFI 
in three dimensions. This 3D spin-echo method accurately localized the focal spot in 
a single scan, and would have direct application to setting up the controller presented 
in Chapter 2. Furthermore, this 3D ARFI technique localized the ultrasound beam in 
fat, which is not possible with traditional beam localization methods that rely on PRF 
thermometry. Finally, Chapter 4 demonstrated a novel method for acquiring 3D ARFI 
displacement maps simultaneously with 3D temperature maps using a multicontrast 
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Additionally, Appendix A details the device I designed and constructed that 
converts the optical trigger emitted by the MRI into an electrical signal compatible 
with the ultrasound generator. This device was initially created for use with the ARFI 
pulse sequences discussed in Chapters 3 and 4, however, the flexibility of its design 
has made it useful for many other projects not discussed in this dissertation including 
ultrasound neurostimulation studies, where ultrasound pulses are triggered by a 
functional MRI pulse sequence, and for perfusion studies, where ultrasound heating 
pulses must be accurately synchronized with temperature imaging.
Appendix B expounds my design of a device for removing oxygen dissolved in 
water. By replacing the manual water boiling method we employed previously, this 
device has saved time, money, and improved the scientific rigor of our experiments.
Many opportunities exist for expanding the work presented in this dissertation. 
Merging the controller work of Chapter 2 with k-space undersampling strategies would 
reduce the time between temperature measurements and enable the controller to make 
faster, more accurate, decisions. Increasing the time horizon over which the controller 
makes predictions could also decrease treatment times (and may require more 
advanced models), as could further investigations into optimal treatment planning. 
Investigating the benefits of applying model predictive control concepts to other 
therapies such as ultrasound assisted immunotherapy, targeted drug-delivery, and 
hyperthermia could also be fruitful. A very real clinical need exists for performing 3D 
ARFI in human organs such as the breast and the brain. These organs are well suited
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to the 3D ARFI pulse sequences presented due to the limited motion they experience, 
and by adding navigator pulses, these techniques could become more robust to motion.
APPENDIX A
DESIGN AND CONSTRUCTION OF A 
TRIGGER CONVERSION DEVICE
A.1 Motivation
In order to perform the acoustic radiation force imaging (ARFI) techniques 
developed in Chapters 3 and 4, it was necessary to synchronize the firing of short 
ultrasound bursts (on the order of 1 -  20 ms in duration) with the motion encoding 
gradients generated by the MRI scanner. Unfortunately, we did not have this 
capability when we endeavored to perform ARFI. This chapter describes the technical 
challenges that needed to be solved as well as the design and construction of the device 
that made synchronization of the ultrasound and MRI pulse sequence possible.
A.2 Design Constraints and Features
The Siemens MRI scanner has a fiber optic output that can be used to generate 
trigger pulses at programmer determined moments during the pulse sequence. The 
converter device’s primary function is to convert the optical trigger from the MRI 
scanner to an electrical trigger signal compatible with the ultrasound generator. 
However, at the time of construction, three technical limitations existed. First, the 
ultrasound generator could only respond to an electrical trigger signal. Second, all 
Siemens MRI pulse sequences group hardware instructions into “event blocks.” These
event blocks are played out sequentially, and it is generally not possible to begin a 
hardware activity in one event block and conclude the activity in a subsequent block. 
Third, the electrical input to the ultrasound generator gates the output of the 
ultrasound, i.e., when the input signal is logical-high, ultrasound emission is 
permitted, and, conversely, emission is prevented when the gating signal is logical- 
low.
It is the second and third techincal limitations that most heavily impacted the 
design of the conversion circuitry. Given that the ultrasound generator uses a gating 
signal, it would seem logical to have the MRI pulse sequence emit an optical pulse for 
the entire duration of the ultrasound burst. However, this would force the pulse 
sequence event block to also last for the duration of the ultrasound burst, and this 
might interfere with the timing of other sequence event blocks. Instead, two very short 
optical pulses, each lasting ~20 |is, are emitted; the first optical pulse indicates when 
the ultrasound emission should begin, and the second when the ultrasound emission 
should end. This solves the event block problem because each optical trigger from the 
MRI can be in two different event blocks, and the trigger is so short that it will not 
impede other sequence activities. This also provides a large degree of flexibility in 
controlling the duration of the ultrasound pulse.
However, using the two-trigger approach requires a more advanced circuit in 
order to control the ultrasound gating signal described in the third limitation; it is no 
longer sufficient to simply convert the optical signal to an electrical signal. Now, the 
conversion circuit must remember the current state (allow vs disallow emission of 
ultrasound), and switch the electrical signal delivered to the ultrasound generator from
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logical-low to logical-high, or vice versa, every time an optical trigger pulse arrives 
from the MRI. This is achieved using a Schmitt-triggered JK Flip-Flop.
However, employing the two-trigger approach to overcome the 
aforementioned technical limitations creates a new safety concern that must be 
mitigated by the trigger conversion device. Under normal conditions, the gating signal 
will remain in the logical-high state for only 1 -  20 ms, and so despite the high acoustic 
power used by ARFI, the ultrasound pulses are safe. However, a variety of technical 
failures could result in the trigger conversion device not receiving the second MRI 
optical trigger, and thus the gating signal controlling the ultrasound burst would 
remain in the logical-high state indefinitely. This could cause significant risk to the 
target tissue in a matter of seconds.
For this reason, a “dead man’s switch” safety mechanism was integrated in the 
trigger converter’s design. When the converter powers on, it resets itself to a known 
state where the gating signal sent to the ultrasound generator is logical-low, preventing 
the emission of ultrasound energy. With the arrival of an optical trigger pulse from the 
MRI, the converter switches the gating signal from logical-low to logical-high while 
simultaneously starting a safety countdown timer. The safety timer’s duration is 
configurable (see Figure A. 1), but is typically 500 ms. If the safety timer expires before 
the second optical trigger arrives from the MRI, the timer forces the gating signal back 
to logical-low thus preventing an unsafe ultrasound emission. Furthermore, the device 
is placed in an error state (indicated visually by a red LED on the front of the device) 
which locks the device into safe mode (logical-low), and ignores further input trigger 
pulses. To return to normal operation, the user must manually press the reset button.
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Figure A.1: Final version of the trigger conversion device. Front panel has an input 
select switch and LED indicators that display which input method is active, an error 
LED that illuminates when the safety timer has expired, a manual reset button to reset 
the device, and a safety timer adjustment screw. The output signals are on the right 
hand side of the device. Both electrical and optical outputs are active simultaneously. 
Between the outputs are two switches that select the trigger type and output mode.
The converter circuit was also designed with flexibility in mind and can be 
operated in several modes. In addition to taking an optical trigger as the input signal, 
the converter device can also take an electrical TTL trigger, and manual push button 
input. The converter device also emits its output signal simultaneously as an electrical 
output (usually connected to the ultrasound generator), and an optical output in case 
other devices need to be triggered or the capabilities of the ultrasound generator 
expand. Additionally, three types of output trigger signal can be selected. The first 
trigger type, labeled as “safe” on the device, implements the two-trigger conversion 
with safety timer as described above. The second mode, labeled “pass thru” on the 
device, bypasses the JK Flip-Flop and safety timer functionality and simply converts 
the optical signal to an equivalent electrical signal. This mode may be used by 
hardware which allows direct triggering by an electrical signal as oppose to gating as 
in the “safe” mode. The last mode, labeled “unsafe” on the device, uses the JK Flip-
Flop functionality but bypasses the safety timer. This would be useful for applications 
where there is no safety risk associated with the gating signal remaining in the active 
state.
There are also three output modes. The first, labeled “Trig” on the device, 
outputs the trigger type selected in the previous paragraph. The second mode, labeled 
“Tmr” on the device, outputs the timer signal instead of the trigger signal. This is useful 
for diagnostics and confirming the timer duration. The last mode, labeled “ON” on 
the device, overrides all triggers and outputs a constant logical-high signal. This would 
be used when triggering is not needed, but when disconnecting the trigger conversion 
device would be too time consuming.
Finally, the device can operate on power provided by an electrical outlet, or 
four standard AA batteries.
A.3 Construction
An initial prototype was designed and implemented on a bread board before a 
printed circuit board was designed (see Figure A.2). The printed circuit board (PCB) 
was designed in PCB Artist (Advanced Circuits and WesDev Ltd). The final circuit 
schematic is shown in Figure A.3, and was laid out on a two-layer PCB (Figure A.4). 
The final PCB design was manufactured by Advanced Circuits. Surface mount 
components were attached to the PCB manually by applying solder paste to each pin 
pad and carefully laying the components on their designated location. The partially 
assembled PCB was then placed on a hot plate, as shown in Figure A.5, until the solder 
began to visually wick into the proper position. The board was then removed from the 
heating pad causing the solder paste to solidify. The PCB was designed to take this
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Figure A.2: The initial prototype conversion circuit implement on a breadboard (left) 
next to the final device (right).
Figure A.3: The final trigger converter circuit schematic
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(b)
Figure A.4: The final PCB layout. (a) Top layer of PCB. (b) Bottom layer of PCB.
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Figure A.5: A hot plate was used to solder surface mount components.
manufacturing step into account since only the top layer would allow for surface 
mount components to be attached using this simple method. The remaining 
components were manually soldered, and the final result can be seen in Figure A.6 . 
An enclosure was designed in Solid Works (Dassault Systemes) and was fabricated 
using 3D printing. To facilitate through-panel connections, all electrical components 
were modeled to ensure accurate placement and hole sizes (see Figure A.7).
A.4 Discussion and Conclusion
The final trigger conversion device has proved to be very reliable, and the flexible 
design has found application beyond the MR-ARFI scenarios presented in this 
dissertation. For instance, the trigger conversion device has enabled precise 
synchronization of heating pulses with MR thermometry sequences, as well as 
neuromodulation applications where the ultrasound is triggered by an fMRI pulse 
sequence. The safety timer is configurable from between 400 ms -  2.8 s, and the device 
can be triggered with optical pulses shorter than 1 |is.
A.5 Parts List
The components used to construct the trigger conversion device are detailed in 
Table A.1. Most of the components used are generic enough that equivalent 
components from another manufacturer could be substituted if desired.
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Figure A.7: Rendering of enclosure, PCB, and mounted components.
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Table A.1: Parts list for trigger conversion device
Passive Components























2.7 Ohm, 5%, 
0.1W, 0603 
47 Ohm, 1%, 
0.25W, 1206 
750, 1%, 0.125W, 
0805 
2K, 1%, 0.1 W, 
0603 
10K, 1%, 0.1W, 
0603 





0.01uF, 5%, 50v, 
MLCC, X7R, 
0603 
0.1uF, 10%, 50v, 
MLCC, X7R, 
0603 
1.0uF, 10%, 50v, 
MLCC, X7R, 
0603 






















































Green, 3 mm (T-1),
Avago HFBR-2528Z 1




LED PC-Mount, Right- Kingbright WP934CB/ID 1
Angle
C&K
ComponentsSlide Switch 1P3T OS103011MA7QP1 2
Slide Switch 2P3T C&KComponents OS203011MA2QP1 1
Push Button 1P Momentary 
Red knob for
ALPS SPPJ311500 2









Logic-AND Quad-AND gate, 2-Input
Texas
Instruments SN74F08D 1
Logic-NOT Hex-Schmitt PhillipsTriggered Inverter N74F14D 1
Positive-Edge Texas
InstrumentsFlip-Flop triggered, SN74109D 1JK Flip-Flop
Negative-Edge
T  pyjiq
Flip-Flop triggered, JK Flip- Instruments SN74112D 1Flop






Peripheral Dual Hi Current Texas SN75451B 1Driver Peripheral Drivers Instruments
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Table A.1 Continued
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Part Type Part Description Manufacturer Part # Qty
Quick- Female 0.187
Connect Quick Connect 2
Terminal terminal
Rubber feet for 0.250” (1/4”) 4Dia. Hole
APPENDIX B
DESIGN AND CONSTRUCTION OF A DEVICE 
FOR THE REMOVAL OF DISSOLVED 
OXYGEN FROM WATER
B.1 Motivation
It is common for the ultrasound beam to be coupled to the target tissue via a 
water bath; however, any oxygen dissolved in the water bath will scatter the beam and 
reduce the beam power delivered to the target. Dissolved oxygen can also cause 
cavitation which has the potential to be dangerous, for example, if bubbles were to 
accumulate on the patient’s skin. Consequently, ensuring the water bath contains low 
amounts of dissolved oxygen is critical for performing safe, high quality, focused 
ultrasound studies. Unfortunately, water normally contains large amounts of dissolved 
oxygen. Additional gases are also likely to be dissolved in water, however, dissolved 
oxygen content is a good indicator of overall gas levels and so monitoring other gases 
is of secondary concern. While, commercially available systems for degassing water 
exist, they are prohibitively expensive, costing approximately $4,000 -  $10,000, and 
do not meet all our performance goals. This chapter discusses the design, construction, 
and testing of an automated device for removing dissolved oxygen from water that is 
economical and highly effective.
B.2 Design Targets
Our target design criteria are summarized in Table B.1. A target dissolved 
oxygen content of 1 ppm (or 1 mg/liter) was selected based on common industry 
standards. For instance, to sell an ultrasound device in Canada, Health Canada 
requires that the ultrasound device have its performance quantified in water that starts 
<= 2 ppm at 22 ± 3°C [1]. Furthermore, water below 4 ppm is absolutely required to 
avoid cavitation, and so to ensure that the water bath is sufficiently degassed for the 
duration of the experiment, even after multiple transfer steps, the initial dissolved 
oxygen content should be < 2 ppm. As a worst-case scenario, we assumed that the de­
ionized water available begins at a dissolved oxygen content of 7 ppm.
A target goal of degassing a water volume of 40 L (approximately 10 gallons) 
to a dissolved oxygen content of 1 ppm within 4 hours was selected. This goal enables 
us to replace the transducer’s water bath multiple times during an experiment as well 
as make phantoms, etc. with water to spare. A 4 hour timeline ensures same-day access 
to degassed water so we can always run sound experiments.
Lastly, the degassing system should require as little human interaction as 
possible while remaining safe and efficient.
B.3 Degassing Methods
Several methods exist for degassing water. The following expanded 
descriptions of each degassing method include paraphrased material available from 
Health Canada and Precision Acoustics [1], [2].
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Table B.1: Target design criteria for the water degassing device
Target Value
Initial dissolved oxygen content 7.0 ppm
Final dissolved oxygen content 1.0 ppm
Volume to be degassed 40 L /  ~10 Gallons
Max time to degas volume 4 hours
Cost $2000
B.3.1.1 Boiling
This is a simple and effective way of degassing water. While boiling periods as 
short as 5 -  15 minutes are sufficient to reduce oxygen levels below 2 ppm, it can take 
a long time to boil a sufficiently large volume of water. Furthermore, the water will 
need to cool before it can be used. During the extended cooling duration, the water is 
regassing, and thus undoing the work that was just done.
B.3.1.2 Vacuum
When subjected to hard vacuums, dissolved oxygen levels can be reduced 
below the 1 ppm. This method of degassing is suited to small volumes of water, but 
can be difficult to implement for larger volumes.
B.3.1.3 Reduced Pressure Recirculation
The system comprises of a high volume pump connected to a standing body of 
water by rigid walled tubing. A pressure restrictor is fitted to the inlet tube, such that 
the pump is attempting to draw water through the tube faster than water is allowed in.
This creates a partial vacuum within the rigid walled tube and any dissolved gas 
bubbles increase in size, and eventually nucleate to form larger bubbles which 
eventually escape to the surface. Oxygen levels of 2-3 ppm can be achieved.
B.3.1.4 Addition of Sodium Sulphite
Sodium sulphite reacts with the dissolved oxygen in the water. Sodium sulphite 
concentrations as low as 4 g/liter will keep oxygen levels below 2 ppm for at least 40 
hours. However, this technique introduces significant ionic content, and can increase 
the water’s conductivity above allowed limits. Furthermore, sodium sulphite solution 
is alkaline and will result in corrosion of many metals including aluminum and nickel, 
and may not be safe for contact with skin.
B.4 Selected Design and Rationale
The boiling method was ruled out because it is impractical for degassing the 
large 40 L target volume. Due to the difficulty of heating such a large volume, the 
water must boiled in batches, and each batch can take 2-3 hours once heating and 
cooling time is accounted for. This method also requires constant human monitoring 
to ensure safety and efficient throughput. Vacuum degassing was also ruled out for 
being too slow and requiring multiple batches, which requires human interaction. 
Adding sodium sulphite risks damaging the transducer and could possibly harm the 
patient.
The selected design combines the vacuum method with the reduced pressure 
recirculation method to provide a device capable of degassing large volumes of water 
without human interaction and without altering the chemistry of the water bath. A
149
schematic of the degasser components is shown in Figure B.1, and the final 
constructed device is shown in Figure B.2. The design uses Liqui-Cel Contactors made 
by Membrana -  Charlotte, a division of Celgard LLC. These modules consist of a 
hydrophobic porous membrane that allow water to pass through the contactor while a 
vacuum pump pulls gas through the membrane and out of the water. Flow rates up to 
3 L/min are achievable using their “MiniModules.” These modules are the second 
most expensive component of the system, and require a vacuum pump that is sold 
separately.
Several types of vacuum pumps exist including oil lubricated rotary pumps, dry 
vane pumps, rotary screw dry pumps, liquid ring pumps, and diaphragm pumps. For 
this application, a diaphragm pump was selected due to its immunity to water vapor 
and low maintenance costs (no oil or filters to clean/replace). The KNF USA Inc. 
LABOPORT N811KVP diaphragm vacuum pump was selected due to its relatively 
low cost and acceptable performance. At a price of $575, the N811KVP pump 
produces a maximum vacuum of 75 Torr. Future systems should consider the 
N816KTP model for $900 which produces a much stronger 15 Torr, vacuum.
To select the appropriate Liqui-Cel Contactor, the performance of four different 
versions was modeled to estimate the time required to reduce 40 L of water with an 
initial dissolved oxygen content of 7 ppm down to the desired target of 1 ppm. 
Membrana provides datasheets that estimate the percentage of oxygen removed at 
various flow rates after one pass through the Liqui-Cel contactor when applying a 
given vacuum. The higher the flow rate, the less oxygen is removed during each pass 
through the contactor; however, the more frequently water is recirculated. The
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Figure B. 1: Schematic diagram of the water degassing device. Repeated passes through 
the Liqui-Cel Contactor extracts dissolved oxygen from the water. PG = Pressure 
Gauge (optional). VG = Vacuum Gauge (optional). FV = Flow control Valve 
(optional). DI-Water = De-ionized water.
Figure B.2: Final version of degasser after construction.
performance of the contactors was derated since the vacuum pump selected can only 
provide a 75 Torr vacuum, and the lowest vacuum strength the contactor datasheets 
gave specifications for was a 50 Torr vacuum. The modeled performance of the four 
Liqui-Cel Modules is summarized in Table B.2. Based on these results, the 
MiniModule 1.7 x 8.75” ($475) was selected since it provides the best opportunity to 
achieve the 4 hour target degassing time while not being significantly more expensive 
than the lower performing models. These estimates also indicate that a flow rate of 
1000 mL /  minute should be sufficient, and this is readily achievable with economical 
water pumps. Many components in Figure B.1, such as the vacuum and pressure 
gauges, are recommended by Membrana for industrial applications, but were omitted 
in this design to reduce cost. Furthermore, some components are readily 
interchangeable with comparable devices. For instance, Membrana instructs users to 
install a 10 |im prefilter to protect the Liqui-Cel Contactor from debris carried in the 
water. A 5 ^m prefilter, normally used for water fountains and refrigerators, was 
selected due to its low cost ($10 -  $15), but other options exist. A DC water pump from 
SHURflo was selected because it allows for easy adjustment of the flow rate. Lastly, it 
was important to use thick-walled tubing for the connection between the contactor and 
the vacuum pump as thin-walled tubing could not withstand the pressure differential 
and collapsed.
B.5 Results and Discussion
To test the degassing device, the 40 L water tank was first filled with deionized 
water. Using a Hanna Instruments HI-9146 (Woonsocket, Rhode Island, USA) 
dissolved oxygen meter, the water tank’s initial dissolved oxygen content was
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measured to be 6.76 ppm. After starting degasser, measurements of the dissolved 
oxygen content were taken periodically, the results of which are shown in Figure B.3. 
The predicted time to reach the target dissolved oxygen content of 1.0 ppm was 
approximately 2.1 hours, and the measured dissolved oxygen content at that time was 
approximately 1.4 ppm. Reaching the 1.0 ppm level did not occur until the device had 
been running for approximately 4 hours. There are several reasons for the anticipated 
degassing rate to be higher than the measured rate. First, the vacuum pump selected 
can produce at most a 75 Torr vacuum, while the Liqui-Cel Contactor lists a minimum 
desired vacuum of 50 Torr. It is likely that the vacuum pump only operates at 
maximum capability during limited scenarios, so the effective vacuum is likely weaker 
than the 75 Torr value quoted by the manufacturer. Second, while the Liqui-Cel 
Contactor performance metrics were derated to account for the difference in vacuum 
strength when predicting their performance, it is possible that the derating applied was 
overly optimistic since it is not obvious how the degassing rate varies with vacuum 
strength. Third, as time progresses, the Liqui-Cel Contactor accumulates water on the 
outside of the membrane which may indicate that its performance is degrading over 
time. Fourth, the predicted performance did not account for regassing of the water in 
the water tank, but this is most certainly occurring. In fact, in Figure B.4 the degasser 
was shut off and the effect of regassing was measured. If the water surface of the water 
tank is properly covered from air exposure, regassing can be kept to approximately 
0.11 ppm per hour, but nevertheless, this effect was missing from the predicted 
contactor performance.
Given these results, the choice to target a 1 ppm dissolved oxygen content now
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Time [Hours]
Figure B.3: Dissolved oxygen content of 40 L water tank while degasser is running. 
The target dissolved oxygen content of 1 ppm is achieved after approximately 4 hours, 
while 1.25 ppm is achieved after only 2.5 hours.
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Figure B.4: Regassing of 40 L water tank once degasser is disabled. When the water is 
covered in the tank, it regasses at a rate of approximately 0.11 ppm per hour. At this 
rate, after 9 hours the water in the tank would still be below 2 ppm.
seems ambitious. That said, the target was achieved by the target duration of 4 hours, 
and it is important to note that very acceptable dissolved oxygen levels of 
approximately 1.3 ppm were achieved after only 2.5 hours. Finally, choosing the 
highest performing contactor was definitely the best choice given that the performance 
predictions were slightly optimistic.
B.6 Parts List and Cost Estimate
The parts required to construct this device, as well as their estimated cost, are 
shown in Table B.3. The vacuum pump can easily be substituted for another model, 
and a higher performing model could significantly improve the system’s performance.
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Table B.3: Parts list for water degassing device
Part Description Price Estimate
Membrana Liqui-Cel Contactor MiniModule 1.7 x 8.75” $475
Water pump SHURflo 100 series, 24V $50
5 pm Sediment Filter Omnipure CL10PF5 inline sediment water filter $15
DC power supply 12V, 10 A $100
Water Tank 
Vacuum Pump
10 Gallon capacity 
RV Supplies 
KNF LABOPORT Mini 
Diaphragm Vacuum Pumps 





Model #: N816KTP (15 Torr) $900
Misc Tubing, Valves, Connectors, etc $50
Total Cost: $1315 - 1640
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B.7 Conclusion
A device for degassing water quickly, efficiently, and effectively has been 
designed, constructed, and tested. This device meets all of the design criteria -  it 
automatically degasses 40 L of water to 1 ppm within 4 hours -  and costs less than 
$1400. This is cheaper and more effective than commercially available systems, and 
eliminates the need for human monitoring. Performance could be improved further by 
investing in a higher performance vacuum pump, optimizing the flow rate through the 
Liqui-Cel Contactor, and investigating more effective methods of preventing 
regassing.
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